WO2019141271A1 - 用于靶向活化cd44分子的脂质体纳米载体递送系统、其制备方法和用途 - Google Patents

用于靶向活化cd44分子的脂质体纳米载体递送系统、其制备方法和用途 Download PDF

Info

Publication number
WO2019141271A1
WO2019141271A1 PCT/CN2019/072499 CN2019072499W WO2019141271A1 WO 2019141271 A1 WO2019141271 A1 WO 2019141271A1 CN 2019072499 W CN2019072499 W CN 2019072499W WO 2019141271 A1 WO2019141271 A1 WO 2019141271A1
Authority
WO
WIPO (PCT)
Prior art keywords
vulnerable plaque
delivery system
plaque
vulnerable
nanocarrier
Prior art date
Application number
PCT/CN2019/072499
Other languages
English (en)
French (fr)
Inventor
马茜
孙洁芳
Original Assignee
北京茵诺医药科技有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 北京茵诺医药科技有限公司 filed Critical 北京茵诺医药科技有限公司
Priority to AU2019208796A priority Critical patent/AU2019208796B2/en
Priority to EP19741349.5A priority patent/EP3744317A4/en
Priority to JP2020538853A priority patent/JP7436367B2/ja
Priority to CN201980001843.4A priority patent/CN110545798B/zh
Priority to KR1020207021204A priority patent/KR20200111185A/ko
Priority to CA3087606A priority patent/CA3087606A1/en
Priority to US16/961,349 priority patent/US20200397926A1/en
Publication of WO2019141271A1 publication Critical patent/WO2019141271A1/zh
Priority to JP2023196823A priority patent/JP2024014986A/ja
Priority to US18/530,122 priority patent/US20240148913A1/en

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
    • A61K51/1217—Dispersions, suspensions, colloids, emulsions, e.g. perfluorinated emulsion, sols
    • A61K51/1234—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
    • A61K47/6913—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome the liposome being modified on its surface by an antibody
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0002—General or multifunctional contrast agents, e.g. chelated agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0063—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres
    • A61K49/0069—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres the agent being in a particular physical galenical form
    • A61K49/0076—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres the agent being in a particular physical galenical form dispersion, suspension, e.g. particles in a liquid, colloid, emulsion
    • A61K49/0084—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres the agent being in a particular physical galenical form dispersion, suspension, e.g. particles in a liquid, colloid, emulsion liposome, i.e. bilayered vesicular structure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/04—X-ray contrast preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/04—X-ray contrast preparations
    • A61K49/0409—Physical forms of mixtures of two different X-ray contrast-enhancing agents, containing at least one X-ray contrast-enhancing agent which is not a halogenated organic compound
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
    • A61K49/1806—Suspensions, emulsions, colloids, dispersions
    • A61K49/1812—Suspensions, emulsions, colloids, dispersions liposomes, polymersomes, e.g. immunoliposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Definitions

  • the invention belongs to the field of targeted drug delivery technology, and in particular relates to a nanocarrier for targeting activated CD44 molecules, in particular to vulnerable fragile plaques, especially a liposome nano delivery system.
  • the invention also relates to the preparation and use of the nanocarriers, in particular liposome nano delivery systems, in particular in the diagnosis, prevention and treatment of vulnerable plaques or diseases associated with vulnerable plaques.
  • Vulnerable plaque refers to atherosclerotic plaques that have a tendency to thrombosis or are likely to progress rapidly into "criminal plaques", including Rupture plaques, aggressive plaques, and partially calcified nodular lesions.
  • the techniques currently used for the diagnosis of vulnerable plaque mainly include coronary angiography, intravascular ultrasound (IVUS), and laser coherence tomography (OCT), but these techniques are all invasive, and the diagnostic resolution and The accuracy is not high, and these diagnostic techniques are expensive, which also limits the clinical popularity to a certain extent. Therefore, there is an urgent need for non-invasive diagnostic techniques and formulations for vulnerable plaque.
  • the current treatment of vulnerable plaques is mainly systemic administration, such as oral statins (hydroxymethylglutaryl coenzyme A (HMG-CoA) reductase inhibitors), aspirin, matrix metalloproteinases (MMPs) inhibition Agents and/or fibrates, etc.
  • HMG-CoA hydroxymethylglutaryl coenzyme A
  • MMPs matrix metalloproteinases
  • statins commonly used in clinical practice are relatively low, such as ⁇ 5% for simvastatin, about 12% for atorvastatin, and about 20% for rosuvastatin.
  • Animal experiments have also confirmed that when the dose of statin is increased to more than 1 mg/kg, it can increase the thickness of the fibrous cap and reduce the volume of plaque, which makes the stability and reversal of oral administration of statins. The effect of the block has encountered a bottleneck.
  • a targeted drug delivery system refers to a drug delivery system that has the ability to target administration. After administration via a route, the drug contained in the targeted drug delivery system is specifically enriched in the target site by a vector with a targeting probe.
  • the targeted drug delivery system is capable of targeting the drug to a particular lesion site and releasing the active ingredient at the target lesion site. Therefore, the targeted drug delivery system can make the drug form a relatively high concentration in the target lesion site, and reduce the dose in the blood circulation, thereby improving the drug effect while suppressing toxic side effects and reducing damage to normal tissues and cells.
  • CD44 is a type of adhesion molecule that is widely distributed on the surface of lymphocytes, monocytes, endothelial cells, and the like.
  • the main ligand for the CD44 molecule is hyaluronic acid (abbreviated as "HA").
  • HA hyaluronic acid
  • CD44 Based on the activation state of the expressed cells, CD44 can be classified into a relatively static state (which cannot bind to HA), an induced activation state (which can bind to HA after activation), and a structurally active state (which can bind to HA without activation), while most normal cells
  • the CD44 of the surface is in a relatively static state and thus cannot be combined with HA.
  • CD44 is not an ideal target with significant targeting specificity. This is because CD44 is widely distributed in the human body, especially on the surface of organs rich in reticuloendothelial. Therefore, the development of a targeted drug delivery system targeting CD44 encounters the problem that if the affinity of CD44 on the surface of the target cell to HA is insufficient to provide significant specificity, then such a targeted drug delivery system will There is no specific targeting performance.
  • the inventors have found that CD44 on the surface of vulnerable plaque cells such as endothelial cells, macrophages, and smooth muscle cells is exposed to the microenvironment of vulnerable plaques (such as under the influence of inflammatory factors) compared to normal cells.
  • the induced activation results in a sudden increase in the ability to bind to HA by several tens of times.
  • This finding suggests that the presence of a large number of activated CD44 molecules on the cell surface at vulnerable plaques provides an ideal target for targeted drug delivery systems with HA as a targeting ligand.
  • the present invention provides a targeted delivery system capable of specifically targeting activated CD44 molecules, particularly targeting vulnerable plaques.
  • loading CD44 activator can promote the further activation of CD44 on the surface of the lesion cells, can amplify the targeting affinity of CD44 for HA in a short time, and significantly increase the concentration of targeting composition bound to the cell surface, which is vulnerable to The diagnosis and treatment of plaques has positive significance.
  • the targeted drug delivery system of the present invention can be loaded with a CD44 activator which can significantly increase the concentration of the tracer or therapeutic compound in a short period of time to improve diagnostic resolution or therapeutic efficacy.
  • the inventors have also found that in vulnerable plaques, with the high activation and overexpression of CD44, the endogenous macromolecular HA is also stimulated to generate a large amount, and binds to CD44 on the cell surface, promoting macrophages and lymphocytes. Aggregation within vulnerable plaques.
  • Such endogenous HA which binds to CD44 on the cell surface, forms a barrier to drug entry and reduces the bioavailability of the drug.
  • the targeted drug delivery system of the present invention can be loaded with a small molecule of hyaluronic acid or a derivative of hyaluronic acid capable of specifically binding to CD44 molecules on the cell surface at the vulnerable plaque, which The competitive binding of endogenous HA on the surface relieves the barrier formed by endogenous HA on the cell surface, which facilitates the smooth entry of the drug into the lesion cells and provides a significant therapeutic effect.
  • the present invention relates to the following aspects:
  • the present invention provides a liposome nanocarrier delivery system for targeting targeted activated CD44 molecules.
  • the present invention provides a liposome nanocarrier delivery system for targeting vulnerable plaque.
  • the invention also provides a method for preparing a liposome nanocarrier delivery system for targeting vulnerable plaques of the invention.
  • the invention also provides a medicament comprising a nanocarrier delivery system for targeting vulnerable plaques of the invention and a pharmaceutically acceptable carrier.
  • the invention also provides a diagnostic formulation comprising a nanocarrier delivery system for targeting vulnerable plaques according to the invention.
  • the invention also provides the use of a nanocarrier delivery system for vulnerable plaques of the invention for the preparation of a medicament for the prevention and/or treatment of a vulnerable plaque or a disease associated with a vulnerable plaque.
  • the invention also provides the use of a nanocarrier delivery system for vulnerable plaques of the invention for the preparation of a diagnostic preparation for the diagnosis of a susceptible plaque or a disease associated with a vulnerable plaque.
  • the invention also provides a method for preventing and/or treating a vulnerable plaque or a disease associated with a vulnerable plaque, the method comprising administering to a subject in need thereof a targeted vulnerable plaque according to the invention Block nanocarrier delivery system.
  • the invention also provides a method for diagnosing a vulnerable plaque or a disease associated with a vulnerable plaque, the method comprising administering to a subject in need thereof the nanocarrier targeting the vulnerable plaque of the invention Delivery system.
  • Vulnerable plaque also known as “unstable plaque” refers to atherosclerotic plaques that have a tendency to thrombosis or are likely to progress rapidly into "criminal plaques”, mainly including ruptured plaques and erosive plaques. Block and partial calcified nodular lesions. A large number of studies have shown that most of the acute myocardial infarction and stroke are caused by the rupture of vulnerable plaques with mild to moderate stenosis and secondary thrombosis.
  • Histological manifestations of vulnerable plaque include active inflammation, thin fibrous cap and large lipid core, endothelial exfoliation with surface platelet aggregation, plaque fissures or damage, and severe stenosis, as well as surface calcification, yellow luster Plaque, intraplaque hemorrhage and positive remodeling.
  • “Disease associated with vulnerable plaque” mainly refers to the “vulnerable plaque” associated with the occurrence and development of the disease, which is characterized by “vulnerable plaque”, caused by “vulnerable plaque” or secondary to “Vulnerable plaque” disease.
  • "Severe diseases associated with vulnerable plaque” mainly include atherosclerosis, coronary atherosclerotic heart disease (including acute coronary syndrome, asymptomatic myocardial ischemia - occult coronary heart disease, angina pectoris, myocardial infarction, Ischemic heart disease, sudden death, in-stent restenosis), cerebral atherosclerosis (including stroke), peripheral vascular atherosclerosis (including occlusive peripheral atherosclerosis, retinal atherosclerosis, Carotid atherosclerosis, renal atherosclerosis, lower extremity atherosclerosis, upper extremity atherosclerosis, atherosclerotic impotence), aortic dissection, hemangioma, thromboembolism, heart failure and heart
  • Targeteted drug delivery system refers to a drug delivery system that has the ability to target administration. After administration via a route, the drug contained in the targeted drug delivery system will be specifically enriched at the target site by the action of a specific carrier or targeting warhead (eg, a targeting ligand).
  • a targeting ligand e.g. a targeting ligand
  • Means currently known for achieving targeted administration include the use of passive targeting properties of various microparticle delivery systems, chemical modification on the surface of microparticle delivery systems, utilization of specific physicochemical properties, and utilization of antibody-mediated targets.
  • a “liposome carrier” is a lipid-like bilayer drug carrier that encapsulates a drug within a lipidoid bilayer to form a microvesicle. It is also possible for the lipid bilayer nanofiber (bicelle) structure to be self-assembled to form a disc with long chain phospholipids and short chain phospholipids or surfactants. The long chain lipid forms the plane of the disc and the short chain phospholipids surround the side edges of the disc. Dimyristoyl phosphatidylcholine (DMPC) is often used as a long-chain phospholipid component, and can change the surface charge of bicelle and achieve more by doping other phospholipid components with the same chain length and different head groups. Feature. The short-chain phospholipids form a high-curvature region to reduce the edge energy of the aggregate, thereby stabilizing the bicelle.
  • DMPC dimyristoyl phosphatidylcholine
  • hyaluronic acid (abbreviated as "HA") is a polymer of a polymer having the formula: (C14H21NO11)n. It is a higher polysaccharide consisting of the units D-glucuronic acid and N-acetylglucosamine. D-glucuronic acid and N-acetylglucosamine are linked by a ⁇ -1,3-glycosidic bond, and the disaccharide units are linked by a ⁇ -1,4-glycosidic bond.
  • hyaluronic acid displays various important physiological functions in the body, such as lubricating joints, regulating the permeability of blood vessel walls, regulating protein, water and electrolyte diffusion and operation, and promoting wound healing. It is especially important that hyaluronic acid has a special water retention effect and is the best moisturizing substance found in nature.
  • Derivative of hyaluronic acid refers to any derivative of hyaluronic acid capable of retaining the specific binding ability of hyaluronic acid to CD44 molecules on the surface of cells at vulnerable plaques, including but not limited to transparent
  • Judging whether a substance is a "derivative of hyaluronic acid” can be achieved by measuring the specific binding ability of the substance to the CD44 molecule on the cell surface at the vulnerable plaque, which is within the skill of those skilled in the art. Inside.
  • CD44 molecule is a type of transmembrane proteoglycan adhesion molecule widely expressed on the cell membrane of lymphocytes, monocytes, endothelial cells, etc., from the extracellular segment, the transmembrane segment and the intracellular segment.
  • the composition of the sections. CD44 molecules can mediate the interaction between a variety of cells and cells, cells and extracellular matrix, participate in the transmission of various signals in the body, and thus change the biological function of cells.
  • the primary ligand for the CD44 molecule is hyaluronic acid, and its receptor-ligand binding to hyaluronic acid determines the adhesion and/or migration of cells in the extracellular matrix.
  • CD44 molecules are also involved in the metabolism of hyaluronic acid.
  • a first aspect of the invention provides a liposome nanocarrier delivery system for targeting activated CD44 molecules, the surface of which is partially modified by a targeting ligand, which is capable of A ligand that specifically binds to an activated CD44 molecule.
  • a second aspect of the invention provides a liposome nanocarrier delivery system for targeting vulnerable plaque, the surface of the nanocarrier being partially modified by a targeting ligand, the targeting ligand being capable of A ligand that specifically binds to a CD44 molecule on the surface of a cell at a vulnerable plaque.
  • the surface of the nanocarrier can also be modified to have a better effect. Modification of PEG on the surface of the carrier can play a long-circulating effect and prolong the half-life of the drug; modification of the transmembrane peptide on the surface of the carrier, self-peptide SEP, or simultaneous modification of the dual ligand can all amplify the effect of the drug.
  • a nanocarrier delivery system wherein the liposome is selected from the group consisting of a lipid bilayer nanopocket (bicelle), a small single compartment liposome, a large single compartment liposome, and more Chamber liposomes.
  • a "liposome carrier” is a lipid-like bilayer drug carrier that encapsulates a drug in a lipidoid bilayer, or a hydrophilic lumen to form a microvesicle, or a disc structure.
  • the lipid bilayer nanobloc can be a disk formed by the self-assembly of a long-chain phospholipid and a short-chain phospholipid or a surfactant.
  • the long chain lipid forms the plane of the disc and the short chain phospholipids surround the side edges of the disc.
  • Dimyristoyl phosphatidylcholine (DMPC) is often used as a long-chain phospholipid component, and can change the surface charge of bicelle and achieve more by doping other phospholipid components with the same chain length and different head groups.
  • the short-chain phospholipid is selected as a bis-n-heptadecanoylphosphatidylcholine to form a high curvature region to reduce the edge energy of the aggregate, thereby stabilizing the bicelle.
  • a liposome nanocarrier delivery system according to the first or second aspect of the invention, wherein the targeting ligand is selected from the group consisting of GAG, collagen, laminin, fibronectin, selectin, osteopontin ( OPN) and monoclonal antibodies HI44a, HI313, A3D8, H90, IM7, or hyaluronic acid or a derivative of hyaluronic acid capable of specifically binding to CD44 molecules on the cell surface at vulnerable plaques.
  • the targeting ligand is selected from the group consisting of GAG, collagen, laminin, fibronectin, selectin, osteopontin ( OPN) and monoclonal antibodies HI44a, HI313, A3D8, H90, IM7, or hyaluronic acid or a derivative of hyaluronic acid capable of specifically binding to CD44 molecules on the cell surface at vulnerable plaques.
  • a nanocarrier delivery system according to the first or second aspect of the invention, wherein the nanocarrier is loaded with a substance for diagnosing, preventing and/or treating a disease associated with the presence of a CD44 molecule activation condition.
  • a hydrogel nanocarrier delivery system according to the first or second aspect of the invention, wherein the nanocarrier is loaded with a substance for diagnosing, preventing and/or treating a vulnerable plaque or a disease associated with a vulnerable plaque ;
  • the substance is a substance for diagnosing a vulnerable plaque or a disease associated with a vulnerable plaque
  • the substance for diagnosing a vulnerable plaque or a disease associated with a vulnerable plaque is a tracer
  • the tracer is selected from the group consisting of a CT tracer, an MRI tracer, and a nucleus tracer;
  • the CT tracer is selected from the group consisting of an iodine nano contrast agent, a gold nano contrast agent, a cerium oxide nano contrast agent, a cerium nano contrast agent, a lanthanide nano contrast agent, or other similar structure tracer; More preferably, it is an iodinated contrast agent or nano gold, or other similar structure of a tracer; further preferably iohexol, iodine acid, ioversol, iodixanol, iopromide, iodobiol, iodine Poole, iopamidol, iodine, iodine, biliary acid, iodobenzoic acid, iodomate, phagoic acid, sodium iodate, iodophenyl ester, iopanoic acid, iodine Acid, sodium iodine iodate, iodine, acetophenone,
  • the MRI tracer is selected from the group consisting of a longitudinal relaxation contrast agent and a transverse relaxation contrast agent; more preferably a paramagnetic contrast agent, a ferromagnetic contrast agent and a supermagnetic contrast agent; further preferably Gd-DTPA and its line type, ring Type polyamine polycarboxylate chelate and manganese porphyrin chelate, macromolecular europium chelate, biomacromolecular modified europium chelate, folic acid modified europium chelate, dendrimer, a liposome modified developer and a tracer containing fluorene fullerene, or other similar structure; more preferably guanidinium citrate, gadolinium citrate, mussel guanamine, guanidine diamine, citric acid Ferric ammonium effervescent particles, paramagnetic iron oxide (Fe3O4NPs), or other similar structure of the tracer, preferably Fe3O4NPs;
  • the nuclide tracer is selected from the group consisting of carbon 14 (14C), carbon 13 (13C), phosphorus 32 (32P), sulfur 35 (35S), iodine 131 (131I), hydrogen 3 (3H), and ⁇ 99 (99Tc). ), fluorine 18 (18F) labeled fluorodeoxyglucose.
  • the substance is one or more of a drug, polypeptide, nucleic acid, and cytokine for use in diagnosing, preventing, and/or treating a disease associated with a vulnerable plaque or a vulnerable plaque.
  • the substance is a CD44 activator
  • the CD44 activator is a CD44 antibody mAb or IL5, IL12, IL18, TNF- ⁇ , LPS;
  • the substance is a small molecule hyaluronic acid or a derivative of hyaluronic acid capable of specifically binding to a CD44 molecule on the surface of a cell at a vulnerable plaque;
  • the small molecule hyaluronic acid or a derivative of hyaluronic acid capable of specifically binding to a CD44 molecule on the cell surface at the vulnerable plaque has a molecular weight ranging from 1 to 500 KDa, preferably 1 to 20 KDa, more It is preferably 2-10 KDa.
  • the nanocarrier is simultaneously loaded with a substance and a CD44 activator for diagnosing, preventing and/or treating a vulnerable plaque or a disease associated with a vulnerable plaque;
  • the nanocarrier is simultaneously loaded with a substance for preventing and/or treating a vulnerable plaque or a disease associated with a vulnerable plaque and hyaluronic acid or a CD44 molecule capable of interacting with a cell surface at a vulnerable plaque a specifically bound derivative of hyaluronic acid;
  • the nanocarrier is simultaneously loaded with a substance for diagnosing a vulnerable plaque or a disease associated with a vulnerable plaque, for preventing and/or treating a vulnerable plaque or a disease associated with a vulnerable plaque.
  • a substance for diagnosing a vulnerable plaque or a disease associated with a vulnerable plaque, for preventing and/or treating a vulnerable plaque or a disease associated with a vulnerable plaque.
  • a substance optionally a CD44 activator, and optionally hyaluronic acid or a derivative of hyaluronic acid capable of specifically binding to a CD44 molecule on the surface of the cell at the vulnerable plaque.
  • the substance is a substance for preventing and/or treating a vulnerable plaque or a disease associated with a vulnerable plaque
  • the substance for preventing and/or treating a vulnerable plaque or a disease associated with a vulnerable plaque is selected from the group consisting of a statin, a fibrate, an antiplatelet drug, a PCSK9 inhibitor, an anticoagulant, Angiotensin-converting enzyme inhibitors (ACEI), calcium antagonists, MMPs inhibitors, beta blockers, glucocorticoids or other anti-inflammatory substances such as the IL-1 antibody canakinumab, and their pharmaceutically acceptable
  • ACEI Angiotensin-converting enzyme inhibitors
  • calcium antagonists calcium antagonists
  • MMPs inhibitors beta blockers
  • glucocorticoids glucocorticoids
  • IL-1 antibody canakinumab glucocorticoids
  • One or more of the salts including active agents of these classes of drugs or substances, and endogenous anti-inflammatory cytokines such as interleukin 10 (IL-10);
  • the substance for preventing and/or treating a vulnerable plaque or a disease associated with a vulnerable plaque is selected from the group consisting of lovastatin, atorvastatin, rosuvastatin, simvastatin, fluvastatin Statins, pitavastatin, pravastatin, bezafibrate, ciprofibrate, clofibrate, gemfibrozil, fenofibrate, probucol, anti-PCSK9 antibodies such as evolocumab, alirocumab, bococizumab, RG7652 LY3015014 and LGT-209, or adnectin such as BMS-962476, antisense RNAi oligonucleotides such as ALN-PCSsc, nucleic acids such as microRNA-33a, microRNA-27a/b, microRNA-106b, microRNA-302, microRNA-758, microRNA -10b, microRNA-19b, microRNA-26, micro
  • a third aspect of the invention provides a method for the preparation of a nano-delivery system for targeting vulnerable plaques according to the first or second aspect, the method comprising the steps of:
  • a suitable amount of phospholipid molecules are dissolved in a suitable organic solvent, and a liposome nanocarrier is prepared by a film hydration method. For a less polar drug molecule, it is necessary to form a film together with the phospholipid molecule in this step.
  • step (2) optionally adding to the nanocarrier delivery system obtained in step (1) an aqueous solution optionally containing a water-soluble substance for diagnosing, preventing and/or treating a disease associated with vulnerable plaque or associated with vulnerable plaque Medium to form a crude suspension;
  • step (3) optionally removing, by dialysis, the unloaded contained in the crude suspension obtained in the step (3) for diagnosing, preventing and/or treating vulnerable plaque or associated with vulnerable plaque
  • the substance of the disease gets a loaded nano delivery system.
  • a fourth aspect of the invention provides a medicament comprising the nanocarrier delivery system of the first aspect or the second aspect, and a pharmaceutically acceptable carrier.
  • a fifth aspect of the invention provides a diagnostic preparation comprising the nanocarrier delivery system of the first aspect or the second aspect.
  • a sixth aspect of the invention provides the nanocarrier delivery system of the first aspect or the second aspect, the medicament of the fourth aspect, or the diagnostic preparation of the fifth aspect, which is prepared for prevention and/or treatment Use in a drug in which a disease associated with activation of a CD44 molecule occurs.
  • a seventh aspect of the invention provides the nanocarrier delivery system of the first aspect or the second aspect, the medicament of the fourth aspect, or the diagnostic preparation of the fifth aspect, which is prepared for prevention and/or treatment Use in medicinal and/or diagnostic preparations of vulnerable plaque or diseases associated with vulnerable plaque.
  • the vulnerable plaque is selected from one or more of a ruptured plaque, an aggressive plaque, and a partially calcified nodular lesion;
  • the disease associated with vulnerable plaque is selected from the group consisting of atherosclerosis, coronary atherosclerotic heart disease (including acute coronary syndrome, asymptomatic myocardial ischemia - occult coronary heart disease, angina pectoris, Myocardial infarction, ischemic heart disease, sudden death, in-stent restenosis, cerebral atherosclerosis (including stroke), peripheral vascular atherosclerosis (including occlusive peripheral atherosclerosis, retinal atherosclerosis) Sclerosis, carotid atherosclerosis, renal atherosclerosis, lower extremity atherosclerosis, upper extremity atherosclerosis, atherosclerotic impotence), aortic dissection, hemangioma, thromboembolism, heart rate One or more of failure and cardiogenic shock.
  • coronary atherosclerotic heart disease including acute coronary syndrome, asymptomatic myocardial ischemia - occult coronary heart disease, angina pectoris, Myocardial infarction
  • An eighth aspect of the invention provides a method for preventing and/or treating a disease associated with the presence of a CD44 molecule activation condition, the method comprising: administering a first aspect or a second aspect to a subject in need thereof The nanocarrier delivery system, the medicament of the fourth aspect, or the diagnostic preparation of the fifth aspect.
  • a ninth aspect of the invention provides a method for preventing, diagnosing and/or treating a vulnerable plaque or a disease associated with a vulnerable plaque, the method comprising: administering a first to a subject in need thereof
  • the nanocarrier delivery system of aspect or the second aspect, the medicament of the fourth aspect, or the diagnostic preparation of the fifth aspect comprising: administering a first to a subject in need thereof
  • the vulnerable plaque is selected from one or more of a ruptured plaque, an aggressive plaque, and a partially calcified nodular lesion.
  • the disease associated with vulnerable plaque is selected from the group consisting of atherosclerosis, coronary atherosclerotic heart disease (including acute coronary syndrome, asymptomatic myocardial ischemia - occult coronary heart disease, angina pectoris) , myocardial infarction, ischemic heart disease, sudden death, in-stent restenosis), cerebral atherosclerosis (including stroke), peripheral vascular atherosclerosis (including occlusive peripheral atherosclerosis, retinal atherosclerosis) Sclerosis, carotid atherosclerosis, renal atherosclerosis, lower extremity atherosclerosis, upper extremity atherosclerosis, atherosclerotic impotence), aortic dissection, hemangioma, thromboembolism, One or more of heart failure and cardiogenic shock.
  • coronary atherosclerotic heart disease including acute coronary syndrome, asymptomatic myocardial ischemia - occult coronary heart disease, angina pectoris
  • a tenth aspect of the invention provides a method for diagnosing a disease associated with the presence of a CD44 molecule activation condition, the method comprising: administering to a subject in need thereof the nanoparticle of the first aspect or the second aspect A carrier delivery system, the medicament of the fourth aspect, or the diagnostic preparation of the fifth aspect.
  • the nanocarrier delivery system of the present invention has the following advantages for diseases in which the CD44 molecule is activated:
  • the nanocarrier delivery system of the present invention is capable of specifically binding to an activated CD44 molecule and is capable of achieving stable sustained release of the drug.
  • CD44 in vulnerable plaques is activated by the extracellular matrix microenvironment, overexpressed in a large amount, and the affinity of CD44-HA is significantly increased, making the interaction between CD44 and HA in vulnerable plaques extremely significant. Affinity specificity.
  • CD44 within the vulnerable plaque constitutes an excellent target for the nanocarrier delivery system of the present invention to target vulnerable plaques.
  • the nanocarrier delivery system targeting vulnerable plaques of the present invention is capable of actively targeting into vulnerable plaques and binding to focal cells.
  • the delivery system can achieve sustained release of the loaded material at the lesion, significantly increasing and continuously maintaining the concentration of the substance in the lesion area, thereby improving the diagnostic or therapeutic effect of the delivery system.
  • the nanocarrier delivery system for targeting vulnerable plaques of the present invention may also be loaded with a CD44 activating substance, i.e., a CD44 activator such as IL5, IL12, IL18, TNF- ⁇ , LPS.
  • a CD44 activating substance i.e., IL5, IL12, IL18, TNF- ⁇ , LPS.
  • Loading CD44 activator can promote the further activation of CD44 on the surface of the lesion cells, can amplify the targeting affinity of CD44 for hyaluronic acid in a short time, and significantly increase the concentration of targeted nanocarrier composition bound to the cell surface, which is vulnerable to vulnerable spots.
  • the tracer diagnosis and treatment of the block is of positive significance because it can significantly increase the concentration of the tracer or therapeutic compound in a short period of time to improve diagnostic resolution or therapeutic effect.
  • Example 1 is an electron micrograph of LP1-(R)-HA in Example 1.
  • Example 2 is an infrared spectrum diagram of LP1-(R)-HA in Example 1.
  • Figure 3 is a graph showing the characterization of LP1-(R)-SP in Example 2.
  • Example 4 is a characteristic diagram of LP1-(R)-HA/Tat in Example 3.
  • Fig. 5 is a characteristic diagram of LP2-(At)-HA in Example 4.
  • Figure 6 is a characterization of LP2-(At)-SEP/IM7 in Example 5.
  • Figure 7 is a graph showing the characterization of LP2-(At/miRNA-33a)-IM7 in Example 6.
  • Figure 8 is a graph showing the characterization of LP2-(AuNP/R)-OPN in Example 7.
  • Figure 9 is a graph showing the characterization of LP1-(Fe3O4/DXMS)-HI44a in Example 8.
  • Figure 10 is a graph showing the characterization of LP1-(Fe3O4/IL-10)-HI44a in Example 9.
  • Figure 11 is a graph showing the characterization of LP1-(Asp/Clo)-Col in Example 10.
  • Figure 12 is a graph showing the characterization of LP1-(F-FDG)-OPN in Example 11.
  • Figure 13 is the effect of long-term placement in Test Example 1 on particle size stability.
  • Figure 14 is the effect of long-term placement in Test Example 1 on the encapsulation efficiency.
  • Figure 15 is the in vitro cumulative release rate of the liposome carrier in Test Example 1.
  • Figure 16 is a nuclear magnetic resonance imaging image of a mouse atherosclerotic vulnerable plaque model constructed in Test Example 2.
  • Figure 17 is a graph showing the results of CD44 content (in semi-quantitative integration) on the surface of endothelial cells at normal arterial wall endothelial cells and arterial vulnerable plaques of model mice.
  • Fig. 18 is a graph showing the results of binding of CD44 to HA on the surface of endothelial cells of normal arterial wall and arterial vulnerable plaques of model mice (indicated by binding force integral).
  • Fig. 19 is a graph showing the results of binding of CD44 to HA on the surface of macrophages in model mice and on the surface of macrophages in arterial vulnerable plaques (indicated by binding force integral).
  • Figure 20 is a graph showing the therapeutic effect of the LP1-(R)-HA, LP1-(R)-SP, LP1-(R)-HA/Tat nano delivery system of the present invention on carotid vulnerable plaques of model mice.
  • Figure 21 is a graph showing the therapeutic effect of LP2-(At)-HA, LP2-(At)-SEP/IM7, LP2-(At/miRNA-33a)-IM7 nano-delivery system on carotid vulnerable plaque in model mice. .
  • Figure 22 is a graph showing the in vivo trace effect of LP2-(AuNP/R)-OPN and other CT tracer nano delivery systems on carotid vulnerable plaques in model mice.
  • Figure 23 is a graph showing the therapeutic effect of the LP2-(AuNP/R)-OPN nano-delivery system on carotid vulnerable plaques in model mice.
  • Figure 24 is an in vivo tracer effect of LP1-(Fe3O4/DXMS)-HI44a, LP1-(Fe3O4/IL-10)-HI44a and other MRI tracer nano delivery systems on carotid vulnerable plaques in model mice. .
  • Figure 25 is a graph showing the therapeutic effect of LP1-(Fe3O4/DXMS)-HI44a, LP1-(Fe3O4/IL-10)-HI44a nano-delivery system on carotid vulnerable plaques in model mice.
  • Figure 26 is a graph showing the therapeutic effect of the LP1-(Asp/Clo)-Col nano-delivery system on rupture of arterial vulnerable plaque in model mice.
  • Figure 27 is a graph showing the in vivo trace effect of the LP1-(F-FDG)-OPN radionuclide tracer nano delivery system on carotid vulnerable plaques in model mice.
  • a liposome nanocapsule LP1-(R)-HA loaded with a therapeutic agent was prepared by a film dispersion method.
  • the surface of the nanovesicles of the above liposome delivery system are partially modified by the targeting ligand hyaluronic acid (abbreviated as "HA”) and are both loaded for the prevention and/or treatment of vulnerable plaque or with vulnerability.
  • HA targeting ligand hyaluronic acid
  • Substance of plaque-related disease rosuvastatin represented by the abbreviation "R"
  • DSPC distearoylphosphatidylcholine
  • DMPE dimyristoyl phosphatidylethanolamine
  • R drug rosuvastatin
  • the molar ratio of the amount to the lipid was 1:10) dissolved in 10 mL of chloroform.
  • the organic solvent was removed by slow rotary evaporation (65 ° C water bath, 90 r/min, 30 min) to form a film on the walls of the vessel.
  • the film was fully hydrated in a constant temperature water bath at 50 ° C to form a crude liposome nanovesicle suspension.
  • the crude liposome nanocapsule suspension was sonicated in a water bath, and finally ultrasonically treated with a probe sonicator for 3 min (amplitude 20, interval 3 s) to condense the unencapsulated drug in the purified liposome nanovesicle suspension.
  • the sugar gel column G-100 was removed.
  • HA molecular weight of about 100 KDa
  • EDC.HCl 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride
  • the g-N-hydroxythiosuccinimide (sulfo-NHS) coupling agent activates the carboxyl group.
  • the activated HA was precipitated by adding absolute ethanol. The precipitate was filtered, washed with ethanol and dried in vacuo to give activated HA.
  • a liposome nanocapsule LP1-(R)-SP loaded with a therapeutic agent was prepared by a film dispersion method.
  • the surface of the nanovesicles of the liposome delivery system described above are all partially modified by a targeting ligand selection protein (abbreviated as "SP") and are both loaded for the prevention and/or treatment of vulnerable plaques or vulnerable plaques.
  • SP targeting ligand selection protein
  • the substance of the block-related disease is rosuvastatin (represented by the abbreviation "R").
  • Liposomal nano-nanovesicles LP1-(R) were prepared as in Example 1.
  • a liposome nanocapsule LP1-(R)-HA/Tat loaded with a therapeutic agent was prepared by a film dispersion method.
  • the surface of the nanovesicles of the above liposome delivery system are partially modified simultaneously by the targeting ligand hyaluronic acid (abbreviated as "HA”) and the transmembrane peptide (Tat), and both are loaded for prevention and/or treatment.
  • HA targeting ligand hyaluronic acid
  • Tat transmembrane peptide
  • Liposomal nanovesicles LP1-(R) were prepared as in Example 1.
  • HA molecular weight of about 10 KDa
  • EDC.HCl 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride
  • N 5 mg
  • a hydroxy sulfosuccinimide (sulfo-NHS) coupling agent activates the carboxyl group.
  • the activated HA was precipitated by adding absolute ethanol. The precipitate was filtered, washed with ethanol and dried in vacuo to give activated HA. This was configured to be an aqueous solution of 1 mg mL-1.
  • Tat peptide 1 mg was thoroughly dissolved in PBS buffer solution, and 0.1 g of 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (EDC.HCl) and 0.12 g of N-hydroxysulfuric acid were added.
  • EDC.HCl 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride
  • a succinimide (sulfo-NHS) coupling agent activates the carboxyl group. After the reaction was stirred at room temperature for 1 hour, ultrafiltration was carried out to remove unreacted organic small molecules.
  • the activated Tat was placed in an aqueous solution of 1 mg mL-1.
  • DMPC dimyristoyl phosphatidylcholine
  • DHPC short-chain bis-n-heptadecanoylphosphatidylcholine
  • DMPE dimyristoyl phosphatidylethanolamine
  • a 10 mL aqueous solution (concentration: 1.0 mg/mL) was added to the round bottom flask, and the flask was placed in a constant temperature water bath at 50 ° C to sufficiently hydrate the film to form a crude liposome nanodisk suspension.
  • the crude liposome nanodisk suspension was sonicated in a water bath and finally sonicated with a probe sonicator for 3 min (amplitude 20, interval 3 s), wherein the unencapsulated drug was removed with a Sephadex column G-100.
  • HA molecular weight of about 100 KDa
  • EDC.HCl 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride
  • the g-N-hydroxythiosuccinimide (sulfo-NHS) coupling agent activates the carboxyl group.
  • the activated HA was precipitated by adding absolute ethanol. The precipitate was filtered, washed with ethanol and dried in vacuo to give activated HA.
  • LP2-(At)-HA Figure 5 is an infrared characterization of LP2-(At)-HA. If it is not necessary to modify the PEG, the above-mentioned PEG-NH 2 -added ring can be saved to obtain LP2-(At)-HA without unmodified PEG.
  • DOTAP short-chain bis-n-heptadecanoylphosphatidylcholine
  • DMPE dimyristoyl phosphatidylethanolamine
  • a 10 mL aqueous solution (concentration: 1.0 mg/mL) was added to the round bottom flask, and the flask was placed in a constant temperature water bath at 50 ° C to sufficiently hydrate the film to form a crude liposome nanodisk suspension.
  • the crude liposome nanodisk suspension was sonicated in a water bath and finally sonicated with a probe sonicator for 3 min (amplitude 20, interval 3 s), ie, the purified liposome disk suspension.
  • the unencapsulated atorvastatin in the purified liposome disk suspension was removed using a Sephadex column G-100. After the filtrate was concentrated, a certain amount of microRNA (miRNA-33a) was added and incubated for 2 hours to promote its binding on the surface of the nanodisk.
  • the product was stored at 4 ° C for low temperature storage.
  • IM7 1 mg was fully dissolved in ultrapure water, and 0.5 mg of 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (EDC.HCl) and 0.5 mg of N-hydroxythione were added.
  • the succinimide (sulfo-NHS) coupling agent activates the carboxyl group and is purified by ultrafiltration to obtain activated sulfo-NHS-IM7.
  • Figure 7 is an infrared representation of LP2-(At/miRNA-33a)-IM7.
  • DMPC dimyristoyl phosphatidylcholine
  • DHPC short-chain bis-n-heptadecanoylphosphatidylcholine
  • DMPE dimyristoyl phosphatidylethanolamine
  • the flask was placed in a constant temperature water bath at 50 ° C to fully hydrate the film for 30 min, and 1 mL of purified AuNPs (1 mM) aqueous solution was added.
  • the crude liposome nanodisk suspension was sonicated in a water bath and finally sonicated with a probe sonicator for 3 min (amplitude 20, interval 3 s), ie, the purified liposome nanodisk suspension.
  • Unencapsulated rosuvastatin and AuNPs in the purified liposome nanodisk suspension were removed using a Sephadex column G-100.
  • OPN 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride
  • EDC.HCl 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride
  • N-hydroxythioaluminum 0.5 mg
  • the sulfo-NHS coupling agent activates the carboxyl group. After stirring the reaction for 1 hour at room temperature, ultrafiltration was centrifuged to obtain activated OPN.
  • the coupling of OPN on LP2-(AuNP/R) was achieved by dissolving 1.0 mL of OPN solution in purified LP2-(AuNP/R) solution.
  • 8 is an infrared characterization diagram of LP2-(AuNP/R)-OPN in Example 7.
  • the raw material was replaced by the above similar preparation method.
  • the inventors also succeeded in preparing the targeted CT tracers LP2-(iodopramine)-OPN, LP2-(iodoxaxanol)-OPN and LP2-(iodofluoroalcohol)- OPN.
  • FeCl3 iron trichloride
  • Fe3O4NPs magnetic iron nanoparticles
  • DSPC distearoylphosphatidylcholine
  • DMPE dimyristoyl phosphatidylethanolamine
  • DMPE dexamethasone
  • the crude liposome vesicle suspension was sonicated in a water bath, and finally ultrasonically treated with a probe sonicator for 3 min (amplitude 20, interval 3 s) to obtain a dispersion system in which liposome vesicles were sufficiently dispersed, that is, a purified liposome sac.
  • Bubble suspension Unencapsulated drug and Fe3O4NPs in the purified liposome vesicle suspension were removed using a Sephadex column G-100.
  • HI44a 1 mg was fully dissolved in ultrapure water, and 0.5 mg of 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (EDC.HCl) and 0.5 mg of N-hydroxythioaluminum were added.
  • EDC.HCl 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride
  • N-hydroxythioaluminum 0.5 mg of N-hydroxythioaluminum.
  • the sulfo-NHS coupling agent activates the carboxyl group. After stirring the reaction for 1 hour at room temperature, ultrafiltration was centrifuged to obtain activated HI44a.
  • FIG. 9 is a graph showing the characterization of LP1-(Fe3O4/DXMS)-HI44a in Example 8.
  • the raw material was replaced by the above similar preparation method.
  • the inventors also succeeded in preparing a targeted MRI tracer LP1-(glucuronide)-HI44a, LP1-( ⁇ diamine)-HI44a and LP1-(cappa oxalate) -HI44a and so on.
  • Example 9 Preparation of Modified Dexamethasone (IL-10) and Magnetic Iron Nanoparticles (Fe 3 O 4 NPs) Liposomal Nanovesicles LP1-(Fe 3 O 4 /IL- Using Monoclonal Antibody (HI44a) Modification 10)
  • DSPC distearoylphosphatidylcholine
  • DMPE dimyristoylphosphatidylethanolamine
  • the crude liposome vesicle suspension was sonicated in a water bath, and finally ultrasonically treated with a probe sonicator for 3 min (amplitude 20, interval 3 s) to obtain a dispersion system in which liposome vesicles were sufficiently dispersed, that is, a purified liposome sac.
  • the suspension was bubbled, and the solution was concentrated and incubated with 1 mg of IL-10 for 10 hours at room temperature to obtain LP1-(Fe 3 O 4 /IL-10).
  • the unencapsulated drug in the purified liposome vesicles was removed with a Sephadex column G-100.
  • HI44a 1 mg was fully dissolved in ultrapure water, and 0.5 mg of 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (EDC.HCl) and 0.5 mg of N-hydroxythioaluminum were added.
  • EDC.HCl 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride
  • N-hydroxythioaluminum 0.5 mg of N-hydroxythioaluminum.
  • the sulfo-NHS coupling agent activates the carboxyl group. After stirring the reaction for 1 hour at room temperature, ultrafiltration was centrifuged to obtain activated HI44a.
  • the HI44a solution was dissolved in the purified LP1-(Fe 3 O 4 /IL-10) solution to realize the coupling of HI44a on LP1-(Fe 3 O 4 /IL-10) to obtain the targeted recognition nanocarrier LP1.
  • Example 10 uses collagen (Col) modification while loading aspirin (Asp), clopidogrel (Clo)
  • the flask was added to 10 mL of pure water and placed in a constant temperature water bath at 50 ° C to fully hydrate the film to form a crude liposomal vesicle suspension.
  • the crude liposome vesicle suspension was sonicated in a water bath, and finally ultrasonically treated with a probe sonicator for 3 min (amplitude 20, interval 3 s) to condense the unencapsulated drug in the purified liposome vesicle suspension with dextran.
  • the rubber column G-100 was removed.
  • FIG. 11 is an infrared characterization of LP1-(Asp/Clo)-Col in Example 10.
  • DSPC distearoylphosphatidylcholine
  • DMPE dimyristoylphosphatidylethanolamine
  • the crude liposome vesicle suspension was sonicated in a water bath, and finally ultrasonically treated with a probe sonicator for 3 min (amplitude 20, interval 3 s) to condense the unencapsulated drug in the purified liposome vesicle suspension with dextran.
  • the rubber column G-100 was removed.
  • the nano-delivery system loaded with the therapeutic agent prepared in Example 1 is taken as an example to prove that the delivery system of the present invention has stable and controllable properties, thereby being suitable for vulnerable plaque or associated with vulnerable plaque. Diagnosis, prevention and treatment of diseases.
  • the carrier drug rosuvastatin, atorvastatin, dexamethasone, aspirin, clopidogrel, fluoro(18F) deoxyglucose have strong UV absorption properties, so it can be obtained by HPLC-UV method (using Waters 2487, Waters Corporation, USA) determined the content of rosuvastatin, atorvastatin, dexamethasone, aspirin, clopidogrel, and fluorine (18F) deoxyglucose.
  • Delivery system of the invention LP1-(R)-HA, LP1-(R)-SP, LP1-(R)-HA/Tat, LP2-(At)-HA, LP2-(At)-SEP/IM7, LP2 -(At/miRNA-33a)-IM7,LP2-(AuNP/R)-OPN,LP1-(Fe3O4/DXMS)-HI44a,LP1-(Fe3O4/IL-10)-HI44a,LP1-(Asp/Clo)
  • the hydrated particle size of -Col, LP1-(F-FDG)-OPN was measured by a laser particle size analyzer (BI-Zeta Plus/90 Plus, Brookhaven Instruments Corporation, USA). The specific results are shown in Table 1. .
  • the method for determining the drug loading is similar to the method for determining the encapsulation rate, except that the calculation method is slightly different. Take a certain mass of drug suspension, add excess methanol to extract the loaded drug, and further use ultrasonic extraction to accelerate the release of the drug from the carrier. The drug content in the obtained liquid was measured by HPLC (Waters 2487, Waters Corporation, USA), and the drug loading amount was calculated by the following formula.
  • the drug content in the resulting liquid was measured by HPLC (Waters 2487, Waters Corporation, USA), and the drug loading amount was calculated by Formula 2.
  • the nano delivery system of the present invention LP1-(R)-HA, LP1-(R)-SP, LP1-(R)-HA/Tat, LP2-(At)-HA, LP2-(At)-SEP/IM7 ,LP2-(At/miRNA-33a)-IM7,LP2-(AuNP/R)-OPN,LP1-(Fe3O4/DXMS)-HI44a,LP1-(Fe3O4/IL-10)-HI44a,LP1-(Asp/ Clo)-Col, LP1-(F-FDG)-OPN were stored at 4 ° C, sampled at different time points, and passed through a laser particle size analyzer (BI-Zeta Plus/90 Plus, Brookhaven Instruments Corporation, USA) The change in the hydrated particle size was examined, and the results are shown in Fig. 13.
  • Figure 13 shows the effect of long-term placement on particle size stability.
  • the drug content in the release solution was measured by HPLC (Waters 2487, Waters Corporation, USA), and the cumulative release rate of the drug was calculated by Formula 3.
  • Equation 3 The meaning of each parameter in Equation 3 is as follows:
  • Ve displacement volume of the release solution, where Ve is 2 mL
  • V0 volume of the release liquid in the release system, where V0 is 50mL
  • Ci concentration of drug in the release solution at the time of the i-th replacement sampling, in ⁇ g/mL
  • M drug the total mass of the drug in the delivery system, in ⁇ g
  • Cn drug concentration in the release system measured after the nth replacement of the release solution.
  • Figure 15 is a graph showing changes in drug cumulative release rate of the liposome delivery system of the present invention.
  • the density of CD44 on the surface of vulnerable plaque endothelial cells and the affinity with HA are studied to select CD44 in the vulnerable plaque as the targeted vulnerable plaque according to the present invention.
  • the target of the delivery system of the block provides an experimental basis.
  • a mouse atherosclerotic vulnerable plaque model was constructed.
  • mice 10 weeks old, body weight 20 ⁇ 1 g were taken as experimental animals.
  • the mice were given an adaptive high-fat diet (fat 10% (w/w), cholesterol 2% (w/w), sodium cholate 0.5% (w/w), and the rest were normal feed for mice) after 4 weeks of feeding.
  • Anesthesia was intraperitoneally injected with 1% sodium pentobarbital (prepared by adding 1 mg of sodium pentobarbital to 100 ml of physiological saline) at a dose of 40 mg/kg.
  • the mouse was fixed on the surgical plate in the supine position, disinfected with the neck centered with 75% (v/v) alcohol, the neck skin was cut longitudinally, and the anterior cervical gland was bluntly separated, on the left side of the trachea.
  • the left common carotid artery can be seen on the side. Carefully separate the common carotid artery to the bifurcation.
  • the silicone tube sleeve with a length of 2.5 mm and an inner diameter of 0.3 mm was placed on the outer circumference of the left common carotid artery.
  • the proximal and distal centripet segments of the cannula were narrowed and fixed by filaments. .
  • LPS lipopolysaccharide
  • mice were placed in a 50 ml syringe (sufficient venting reserved) to cause restrictive mental stress, 6 hours/day, 5 days per week for a total of 6 weeks.
  • the mouse atherosclerotic vulnerable plaque model was completed at 14 weeks postoperatively.
  • Figure 16 (a) and (b) show the MRI image of the mouse atherosclerotic vulnerable plaque model. It can be seen from the arrow pointing part that the left carotid plaque has formed. Successful modeling, right arterial artery can be compared as normal arterial wall.
  • the endothelial cells of the normal arterial vascular endothelial cells and arterial vulnerable plaques of the model mice were taken for CD44 determination by immunohistochemical staining and image analysis.
  • the specific experimental methods are as follows:
  • the mouse carotid atherosclerotic vulnerable plaque specimens were fixed with 10 mL/L formaldehyde solution, paraffin-embedded, 4 ⁇ m sections, conventional dewaxing, hydration treatment, and avidin-biotin-enzyme complex method. (SABC) detects CD44 content.
  • the specimen was immersed in a 30 mL/L H2O2 aqueous solution to block the activity of endogenous peroxidase, and subjected to antigen microwave repair in a citrate buffer. Then 50 g/L bovine serum albumin (BSA) blocking solution was added dropwise and allowed to stand at room temperature for 20 min.
  • BSA bovine serum albumin
  • a murine anti-CD44 polyclonal antibody (1:100) was added dropwise, placed in a refrigerator at 4 ° C overnight, and incubated at 37 ° C for 1 h. After washing, biotinylated goat anti-mouse IgG was added dropwise and reacted at 37 ° C for 30 min. Then, it was washed with phosphate buffered saline (PBS), and horseradish peroxidase-labeled SABC complex was added dropwise, and incubated at 37 ° C for 20 min; each step was washed with PBS. Finally, color development was performed with DAB (controlled under a microscope when developing color), followed by counterstaining, dehydration and mounting with hematoxylin.
  • PBS phosphate buffered saline
  • Sections were analyzed by immunohistochemical analysis system of BI-2000 image analysis system. Three sections were collected for normal arterial endothelial cells and endothelial cells of arterial vulnerable plaques, and five representative fields were randomly selected.
  • the positive expression of CD44 was: cell membrane, cytoplasm was brownish/tanose and the background was clear, and the darker the color, the stronger the expression of CD44. No brown-yellow particles were found to be negative for CD44 expression.
  • the mean absorbance (A) values of positive cells in the endothelial cells of normal arterial endothelial cells and arterial vulnerable plaques were measured and compared. The result is shown in Fig. 17.
  • Figure 17 shows the results of surface CD44 content determination (in semi-quantitative integration) of endothelial cells at normal arterial wall endothelial cells and arterial vulnerable plaques of model mice. As shown, the surface CD44 content of endothelial cells at arterial vulnerable plaques was approximately 2.3 times that of normal arterial endothelial cells.
  • Natural ligands for CD44 include: HA, GAG, collagen, laminin, fibronectin, selectin, osteopontin (OPN), and monoclonal antibodies HI44a, HI313, A3D8, H90, IM7, and the like.
  • the normal arterial wall endothelial cells of the model mice and the endothelial cells at the vulnerable plaques of the arteries were added with a ligand/antibody labeled with aminofluorescein at a concentration of 10 mg/ml, and the improved Iggar medium was used in Durbreco. (DMEM) medium (containing 10% by volume of calf serum, 100 U/ml penicillin, 100 U/ml streptomycin) was cultured in a 37 ° C, 5% CO 2 incubator. After 30 minutes, the mean fluorescence intensity (MFI) was determined by flow cytometry (CytoFLEX, Beckman Coulter, USA), and the binding integral of FL-ligand/antibody on both cell surfaces was calculated (to normal arterial vessels). The binding of CD44 to the ligand/antibody of the wall endothelial cells is 1). The result is shown in Fig. 18.
  • the binding force of CD44 to HA on the surface of endothelial cells at the vulnerable plaque of arteries was approximately 24 times that of the endothelial cell surface of normal arterial wall. This indicates that most of the CD44 on the surface of endothelial cells of normal arterial wall is in a quiescent state that cannot bind to ligand HA, and CD44 on the surface of endothelial cells at the vulnerable plaque of arteries is activated by factors such as inflammatory factors in the internal environment. The affinity with HA has increased significantly.
  • CD44 other ligands similar to HA, the binding capacity of CD44 and GAG on the surface of vulnerable plaque endothelial cells is 22 times that of normal cells, and the binding capacity of CD44 and collagen in vulnerable plaque endothelial cells is 21 times that of normal cells.
  • the binding capacity of CD44 and laminin in vulnerable plaque endothelial cells is 16 times that of normal cells.
  • the binding force of CD44 and fibronectin in vulnerable plaque endothelial cells is 18 times that of normal cells, and vulnerable spots are vulnerable.
  • the binding capacity of CD44 and selectin in block endothelial cells was 19 times that of normal cells, and the binding capacity of CD44 and osteopontin in vulnerable plaque endothelial cells was 17 times that of normal cells.
  • CD44 monoclonal antibodies Similar results were observed for CD44 monoclonal antibodies: the binding of CD44 to H144a on the surface of vulnerable plaque endothelial cells was 15 times that of normal cells, and the binding capacity of CD44 and H1313 in vulnerable plaque endothelial cells was 21 times that of normal cells. The binding capacity of CD44 and A3D8 in vulnerable plaque endothelial cells is 17 times that of normal cells. The binding capacity of CD44 and H90 in vulnerable plaque endothelial cells is 9 times that of normal cells, and vulnerable plaque endothelial cells CD44 and IM7. The binding force integral is 8 times that of normal cells.
  • the macrophages in the peritoneal cavity of the model mice and the macrophages in the vulnerable plaques of the arteries were added to the ligand/antibody labeled with aminofluorescein at a concentration of 10 mg/ml, and the volume fraction was 10% calf serum, 100 U/ml penicillin, 100 U/ml streptomycin) were cultured in a 37 ° C, 5% CO 2 incubator. After 30 minutes, the mean fluorescence intensity (MFI) was determined using a flow cytometer (CytoFLEX, Beckman Coulter, USA) and the binding integral of FL-HA on both cell surfaces was calculated (with extra-plaque macrophages) The CD44 on the cell surface has a ligand/antibody affinity of 1). The result is shown in FIG.
  • the binding force of CD44-HA on the surface of macrophages in arterial vulnerable plaques was about 40 times that of CD44-HA on the surface of extraplaque macrophages. This indicates that CD44 on the surface of macrophages in arterial vulnerable plaques is also activated by factors such as inflammatory factors in the internal environment, and the affinity with HA is significantly increased.
  • CD44 other ligands similar to HA, the binding capacity of CD44 and GAG on the surface of vulnerable plaque macrophages is 33 times that of normal cells, and the binding integral of CD44 and collagen in vulnerable plaque macrophages is normal cells. 38 times, the binding capacity of CD44 and laminin in vulnerable plaque macrophages is 37 times that of normal cells, and the binding force of CD44 and fibronectin in vulnerable plaque macrophages is 35 times that of normal cells.
  • the binding capacity of vulnerable plaque macrophage CD44 to selectin is 33 times that of normal cells, and the binding capacity of vulnerable plaque macrophage CD44 to osteopontin is 33 times that of normal cells.
  • CD44 monoclonal antibodies Similar results were observed for CD44 monoclonal antibodies: the binding of CD44 to H144a on the surface of vulnerable plaque macrophages was 17 times that of normal cells, and the binding integral of vulnerable plaque macrophages CD44 and H1313 was normal cells. 20 times, the binding strength of CD44 and A3D8 in vulnerable plaque macrophages is 16 times that of normal cells. The binding force of CD44 and H90 in vulnerable plaque macrophages is 9 times that of normal cells, and vulnerable plaques are giant. The binding capacity of phagocytic CD44 to IM7 is 10 times that of normal cells.
  • Test Example 3 In vivo experiment of the effects of the LP1-(R)-HA, LP1-(R)-SP, LP1-(R)-HA/Tat rosuvastatin delivery system of the present invention on vulnerable plaque of arteries
  • Hyaluronic acid (HA) and selectin (SP) are ligands for CD44, which can target vulnerable plaques.
  • Rosuvastatin (R) has the effect of reversing plaque, transmembrane peptide (Tat) Can increase local penetration and aggregation of drugs.
  • the purpose of this example was to demonstrate the in vivo therapeutic effect of the LP1-(R)-HA, LP1-(R)-SP, LP1-(R)-HA/Tat vector delivery system of the present invention on arterial vulnerable plaques. .
  • a physiological saline solution of free rosuvastatin was formulated, and a liposome nano delivery system loaded with a therapeutic agent was prepared by the method described in the above Examples 1-3.
  • SPF-grade ApoE-/- mice 42 animals, 5-6 weeks old, body weight 20 ⁇ 1 g were taken as experimental animals.
  • the mice were given an adaptive high-fat diet (fat 10% (w/w), cholesterol 2% (w/w), sodium cholate 0.5% (w/w), and the rest were normal feed for mice) after 4 weeks of feeding.
  • Anesthesia was intraperitoneally injected with 1% sodium pentobarbital (prepared by adding 1 mg of sodium pentobarbital to 100 ml of physiological saline) at a dose of 40 mg/kg.
  • the mouse was fixed on the surgical plate in the supine position, disinfected with the neck centered with 75% (v/v) alcohol, the neck skin was cut longitudinally, and the anterior cervical gland was bluntly separated, on the left side of the trachea.
  • the left common carotid artery can be seen on the side. Carefully separate the common carotid artery to the bifurcation.
  • the silicone tube sleeve with a length of 2.5 mm and an inner diameter of 0.3 mm was placed on the outer circumference of the left common carotid artery.
  • the proximal and distal centripet segments of the cannula were narrowed and fixed by filaments. .
  • LPS lipopolysaccharide
  • mice were placed in a 50 ml syringe (sufficient venting reserved) to cause restrictive mental stress, 6 hours/day, 5 days per week for a total of 6 weeks.
  • the mouse atherosclerotic vulnerable plaque model was completed at 14 weeks postoperatively.
  • the experimental animals were randomly divided into the following groups, 6 in each group:
  • Vulnerable plaque model control group this group of animals did not undergo any therapeutic treatment
  • Rosuvastatin intragastric administration intragastric administration at a dose of 10 mg rosuvastatin / kg body weight;
  • Rosuvastatin intravenous group intravenous administration at a dose of 0.66 mg rosuvastatin / kg body weight;
  • LP1-(R)-HA group intravenous administration at a dose of 0.66 mg rosuvastatin/kg body weight;
  • LP1-(R)-SP group intravenous administration at a dose of 0.66 mg rosuvastatin/kg body weight;
  • LP1-(R)-HA/Tat group intravenous administration treatment at a dose of 0.66 mg rosuvastatin/kg body weight.
  • the treatment group was treated once every other day for a total of 5 treatments.
  • carotid MRI scans were performed before and after treatment to detect plaque and lumen area, and the percentage of plaque progression was calculated.
  • Percentage of plaque progression (plaque area after treatment - plaque area before treatment) / lumen area.
  • Figure 20 is a graph showing the in vivo therapeutic effect of the LP1-(R)-HA, LP1-(R)-SP, LP1-(R)-HA/Tat vector delivery system of the present invention on arterial vulnerable plaques.
  • the control group (not given any treatment) had an atherosclerosis progression of 36.23%; rosuvastatin was used to treat the plaque.
  • LP1-(R)-HA group eliminated plaque 10.87%
  • LP1-(R)-SP eliminated plaque 8.74%
  • LP1-(R)-HA/Tat group eliminated plaque 13.2 %.
  • rosuvastatin has a certain therapeutic effect, whether it is administered by intragastric administration or intravenous administration, but it cannot prevent the damage.
  • the plaque continues to grow.
  • rosuvastatin was formulated in the nano-delivery system of the present invention, its therapeutic effect on vulnerable plaques was significantly improved, and treatment for reversing plaque growth (reducing plaque) was achieved. The effect is better with nano-systems with functional modifications.
  • Test Example 4 In vivo experiment of the effects of the LP2-(At)-HA, LP2-(At)-SEP/IM7, LP2-(At/miRNA-33a)-IM7 delivery system of the present invention on vulnerable plaque of arteries
  • Hyaluronic acid (HA) and IM7 are ligands for CD44, which can play a role in targeting vulnerable plaque.
  • Atorvastatin (At) has the effect of reversing plaque, and self-peptide (SEP) can increase drug penetration.
  • SEP self-peptide
  • miRNA-33a can increase cholesterol efflux.
  • the purpose of this example was to verify the LP2-(At)-HA, LP2-(At)-SEP/IM7, LP2-(At/miRNA-33a)-IM7 vector delivery system of the present invention for arterial vulnerable plaque The in vivo therapeutic effect.
  • a physiological saline solution of free atorvastatin was prepared, and a hollow silica nano delivery system loaded with a therapeutic agent was prepared by the method described in the above Examples 4-6.
  • the experimental animals were randomly divided into the following groups, 6 in each group:
  • Vulnerable plaque model control group this group of animals did not undergo any therapeutic treatment
  • Atorvastatin gavage group intragastric administration at a dose of 20 mg atorvastatin / kg body weight;
  • Atorvastatin intravenous group intravenous administration of 1.2 mg atorvastatin / kg body weight;
  • PEG-free LP2-(At)-HA group intravenous administration at a dose of 1.2 mg atorvastatin/kg body weight;
  • LP2-(At)-HA group intravenous administration at a dose of 1.2 mg atorvastatin/kg body weight;
  • LP2-(At)-IM7 group intravenous administration at a dose of 1.2 mg atorvastatin/kg body weight;
  • LP2-(At)-SEP/IM7 group intravenous administration at a dose of 1.2 mg atorvastatin/kg body weight;
  • LP2-(At/miRNA-33a)-IM7 group intravenous administration treatment at a dose of 1.2 mg atorvastatin/kg body weight.
  • the treatment group was treated once every other day for a total of 5 treatments.
  • carotid MRI scans were performed before and after treatment to detect plaque and lumen area, and the percentage of plaque progression was calculated.
  • Percentage of plaque progression (plaque area after treatment - plaque area before treatment) / lumen area.
  • Figure 21 is a graph showing the in vivo therapeutic effect of the LP2-(At)-HA, LP2-(At)-SEP/IM7, LP2-(At/miRNA-33a)-IM7 system of the present invention on arterial vulnerable plaques.
  • the atherosclerosis of the control group progressed by 34.87%; the atorvastatin treatment can delay the plaque Progress, but also progressed 33.21%; atorvastatin intravenous injection also delayed plaque progression, but also progressed 32.98%; while targeted nano drug-loading treatment significantly curbed plaque progression, and even plaque Volume reversal and regression, PEG-free LP2-(At)-HA group eliminated plaque by 6.9%, LP2-(At)-HA group eliminated plaque 12.65%, LP2-(At)-IM7 group resulted in plaque The block was eliminated by 5.1%, the LP2-(At)-SEP/IM7 group eliminated 12.43%, and the LP2-(At/miRNA-33a)-IM7 group eliminated the plaque by 14.22%.
  • atorvastatin has a certain therapeutic effect, whether it is administered by intragastric administration or intravenous administration, but it cannot prevent the damage.
  • the plaque continues to grow.
  • atorvastatin was formulated in the liposome nano delivery system of the present invention, its therapeutic effect on vulnerable plaques was significantly improved, and the plaque growth was reversed (reducing plaques) ) The therapeutic effect.
  • Nanocarriers modified with PEG or SEP function are more effective, while nanocarriers loaded with statins and nucleic acids are more effective.
  • Test Example 5 In vivo experiment of the effect of the LP2-(AuNP/R)-OPN delivery system of the present invention on vulnerable plaque of arteries (CT tracing and treatment dual function)
  • Osteopontin is a ligand for CD44, which acts to target vulnerable plaques. Rosuvastatin (R) has the effect of reversing plaques. Nanogold (AuNP) is a CT tracer. The purpose of this example was to verify the in vivo tracing and therapeutic effects of the loaded CT tracer and rosuvastatin nano delivery systems of the present invention on arterial vulnerable plaques.
  • a physiological saline solution of free rosuvastatin was formulated, and a liposome nano delivery system loaded with a CT tracer and a therapeutic agent was prepared by the method described in the above Example 7.
  • the experimental animals were randomly divided into the following groups, 6 in each group:
  • the group of free nano gold particles the dosage of nano gold is 0.1 mg/kg body weight;
  • LP2-(AuNP/R)-OPN group nano gold was administered at a dose of 0.1 mg/kg body weight
  • LP2-(iodopramine)-OPN group iopromide is administered at a dose of 0.1 mg/kg body weight;
  • LP2-(iodoxaxan)-OPN group iodixanol is administered at a dose of 0.1 mg/kg body weight;
  • LP2-(Iodofluoroalcohol)-OPN group Iodine fluoride was administered at a dose of 0.1 mg/kg body weight.
  • Each experimental group was injected with the corresponding tracer through the tail vein, and CT imaging was performed before administration and 2 hours after administration to observe the identification of atherosclerotic vulnerable plaque in each group.
  • the experimental animals were randomly divided into the following groups, 6 in each group:
  • Vulnerable plaque model control group this group of animals did not undergo any therapeutic treatment
  • Rosuvastatin intragastric administration intragastric administration at a dose of 10 mg rosuvastatin / kg body weight;
  • Rosuvastatin intravenous group intravenous administration at a dose of 0.67 mg rosuvastatin / kg body weight;
  • LP2-(AuNP/R)-OPN group intravenous administration at a dose of 0.67 mg rosuvastatin/kg body weight;
  • the treatment group was treated once every other day for a total of 5 treatments.
  • carotid MRI scans were performed before and after treatment to detect plaque and lumen area, and the percentage of plaque progression was calculated.
  • Percentage of plaque progression (plaque area after treatment - plaque area before treatment) / lumen area.
  • Figure 22 illustrates the in vivo tracer effect of the load tracer-based liposome delivery system of the present invention on arterial vulnerable plaque.
  • the free nanogold particles showed a certain trace effect on arterial vulnerable plaques in mice.
  • their traceability to vulnerable plaques is A very significant improvement.
  • the use of the liposome delivery system of the surface modified with the targeting ligand of the present invention can significantly improve the recognition of arterial vulnerable plaque by nano gold compared to the free nano gold particles. Better tracer effect.
  • Figure 23 is a graph showing the in vivo therapeutic effect of the LP2-(AuNP/R)-OPN system of the present invention on arterial vulnerable plaque.
  • the control group (not given any treatment) developed atherosclerosis 31.23%; rosuvastatin treatment can delay plaque Progress, but also progressed by 30.9%; rosuvastatin intravenous injection also delayed plaque progression, but also progressed by 25.34%; while targeted nano drug-loading treatment significantly curbed plaque progression, and even plaque
  • the volume reversal and regression, LP2-(AuNP/R)-OPN caused the plaque to resolve by 8.32%.
  • rosuvastatin has a certain therapeutic effect, whether it is administered by intragastric administration or intravenous administration, but it cannot prevent the damage.
  • the plaque continues to grow.
  • rosuvastatin and nanogold are formulated in the nano-delivery system of the present invention, the diagnostic and therapeutic effects of vulnerable plaques are significantly improved, and early warning and reversal of high-risk patients are performed.
  • Test Example 6 In vivo tracer test (MRI tracing) and anti-inflammatory treatment of arterial vulnerable plaques by LP1-(Fe3O4/DXMS)-HI44a, LP1-(Fe3O4/IL-10)-HI44a delivery system of the present invention
  • Monoclonal antibody (HI44a) is an antibody against CD44 that acts as a target for vulnerable plaque.
  • Dexamethasone (DXMS) has anti-inflammatory effects and inhibits plaque progression.
  • Fe3O4 is an MRI tracer. The purpose of this example was to verify the in vivo tracing and therapeutic effects of the loaded MRI tracer and dexamethasone nano-delivery system on arterial vulnerable plaques of the present invention.
  • gadolinium citrate, guanidine diamine, and guanidinic acid can also be prepared into nano-formulations, showing a targeted MRI tracer effect.
  • a liposome nano delivery system loaded with an MRI tracer and a therapeutic agent was prepared by the method described in the above Examples 8-9.
  • the experimental animals were randomly divided into the following groups, 6 in each group:
  • Free Fe3O4 group Fe3O4 is administered at a dose of 0.1 mg/kg body weight
  • Fe3O4 is administered at a dose of 0.1 mg/kg body weight
  • Fe3O4 is administered at a dose of 0.1 mg/kg body weight
  • LP1-(glucuronide)-HI44a group gadolinium citrate is administered at a dose of 0.1 mg/kg body weight;
  • LP1-(nondiamine)-HI44a group guanidine diamine is administered at a dose of 0.1 mg/kg body weight;
  • the LP1-(capacic acid)-HI44a group guanidinic acid was administered at a dose of 0.1 mg/kg body weight.
  • Each experimental group was injected with the corresponding tracer through the tail vein, and MRI imaging was performed before administration and 2 hours after administration to observe the identification of atherosclerotic vulnerable plaque in each group.
  • the experimental animals were randomly divided into the following groups, 6 in each group:
  • Vulnerable plaque model control group this group of animals did not undergo any therapeutic treatment
  • LP1-(Fe3O4/DXMS)-HI44a group intravenous administration at a dose of 0.1 mg dexamethasone/kg body weight;
  • LP1-(Fe3O4/IL-10)-HI44a group intravenous administration was carried out at a dose of 0.1 micromolar IL-10/kg body weight.
  • the treatment group was treated once every other day for a total of 5 treatments.
  • carotid MRI scans were performed before and after treatment to detect plaque and lumen area, and the percentage of plaque progression was calculated.
  • Percentage of plaque progression (plaque area after treatment - plaque area before treatment) / lumen area.
  • Figure 24 is a graph showing the in vivo tracer effect of the load tracer-loaded liposome delivery system of the present invention on arterial vulnerable plaque.
  • the free Fe3O4 particles showed a certain tracer effect on arterial vulnerable plaques in mice.
  • the traceability to vulnerable plaques is significantly improved, using other MRI nanocontrast agents, vulnerable
  • the tracer effect of the plaque is also very good.
  • administration of a liposome delivery system with a surface-modified ligand with a targeting agent according to the present invention can significantly enhance the recognition of arterial vulnerable plaque by MRI tracer compared to a free MRI tracer. The effect is to produce a better tracer effect.
  • Figure 25 is a graph showing the in vivo therapeutic effect of the LP1-(Fe3O4/DXMS)-HI44a system and the LP1-(Fe3O4/IL-10)-HI44a system of the present invention on arterial vulnerable plaques.
  • the atherosclerosis of the control group (not given any treatment treatment) progressed by 23.65%; while the targeted nano drug-loading treatment significantly suppressed the plaque.
  • LP1-(Fe3O4/DXMS)-HI44a caused the plaque to subside 9.54%
  • LP1-(Fe3O4/IL-10)-HI44a caused the plaque to subside 5.43%.
  • an anti-inflammatory substance such as dexamethasone or IL-10
  • it is suitable for vulnerable plaque.
  • Diagnostic and therapeutic effects have improved significantly, and have served as a warning for high-risk patients and to reverse the effects of plaque growth (reducing plaque).
  • Fe3O4 can be used for MRI imaging to monitor the effect of the disease in real time.
  • Test Example 7 In vivo experiment of the effect of the LP1-(Asp/Clo)-Col delivery system of the present invention on vulnerable plaque of arteries
  • Aspirin (Asp) and clopidogrel (Clo) are antiplatelet agents that reduce platelet aggregation and reduce cardiovascular mortality.
  • the purpose of this example was to demonstrate the in vivo therapeutic effect of the LP1-(Asp/Clo)-Col vector delivery system of the present invention on arterial vulnerable plaques.
  • a physiological saline solution of free aspirin and clopidogrel was prepared, and a liposome nano delivery system loaded with a therapeutic agent was prepared by the method described in the above Example 10.
  • the experimental animals were randomly divided into the following groups, 10 in each group:
  • Plaque rupture model control group this group of animals did not undergo any therapeutic treatment
  • Aspirin and clopidogrel in the gavage group intragastric administration at a dose of 100 mg of aspirin/kg body weight and 75 mg of clopidogrel/kg body weight;
  • LP1-(Asp/Clo)-Col group intravenous administration treatment at a dose of 10 mg of aspirin/kg body weight and 7.5 mg of clopidogrel/kg body weight;
  • the treatment group was treated once every other day for a total of 5 treatments.
  • the mortality of the mice in January was observed, and the bleeding time (BT) of the mice was detected by tail-tailing.
  • Figure 26 is a graph showing the in vivo therapeutic effect of the LP1-(Asp/Clo)-Col system of the present invention on arterial vulnerable plaques.
  • mice in the control group had a 50% mortality rate; intragastric administration with aspirin and clopidogrel reduced mortality to 30%; LP1-(Asp/Clo)- Col treatment can reduce mortality to 10%.
  • the LP1-(Asp/Clo)-Col group was not significantly prolonged, while the bleeding time was significantly prolonged in mice taking oral aspirin and clopidogrel.
  • oral dual antiplatelet therapy can reduce mortality, but prolong bleeding time and increase bleeding risk.
  • the loading of the antiplatelet drug into the nano delivery system of the present invention provides better efficacy than the oral drug without increasing the risk of bleeding.
  • Test Example 8 In vivo experiment of the effect of the LP1-(F-FDG)-OPN delivery system of the present invention on vulnerable plaque of arteries
  • Osteopontin is a ligand for CD44, which acts to target vulnerable plaques. Rosuvastatin (R) has the effect of reversing plaque. Fluoride 18 deoxyglucose (F-FDG) is a nuclides. Tracer. The purpose of this example was to verify the in vivo tracing and therapeutic effects of the loaded nuclide tracer-loaded liposome nanodelivery system on arterial vulnerable plaques.
  • a physiological saline solution of free rosuvastatin was formulated, and a liposome nano-delivery system loaded with a radionuclide tracer was prepared by the method described in the above Example 11.
  • the experimental animals were randomly divided into the following groups, 6 in each group:
  • Free F-FDG group F-FDG was administered at a dose of 2 mSv/kg body weight
  • LP1-(F-FDG)-OPN group nano gold was administered at a dose of 2 mSv/kg body weight
  • LP1-(99mTc)-OPN group iopromide is administered at a dose of 2 mSv/kg body weight;
  • the LP1-(I-131)-OPN group; iodixanol was administered at a dose of 2 mSv/kg body weight.
  • Each experimental group was injected with the corresponding tracer through the tail vein, and the radionuclide imaging was performed before the administration and 2 hours after the administration, and the identification of the atherosclerotic vulnerable plaque in each group was observed.
  • Figure 27 is a graph showing the in vivo tracer effect of the loaded nuclide tracer-loaded liposome delivery system on arterial vulnerable plaques of the present invention.
  • free F-FDG did not exhibit a tracer effect on arterial vulnerable plaque in mice.
  • F-FDG, ⁇ 99 (99mTc), iodine 131 (I-131) was formulated in a targeted liposome delivery system, its traceability to vulnerable plaques was significantly improved.
  • the use of the liposome delivery system of the surface modified with targeting ligands of the present invention can significantly enhance the recognition of arterial vulnerable plaques by radionuclide tracers compared to free F-FDG. The effect is to produce a good tracer effect.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Dispersion Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Inorganic Chemistry (AREA)
  • Radiology & Medical Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Vascular Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Biophysics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

一种用于靶向活化的CD44分子的脂质体纳米载体递送系统及其制备方法和用途。所述纳米载体的表面部分地被靶向配体修饰，所述靶向配体是能与活化的CD44分子特异性结合的配体；所述的脂质体纳米载体递送系统可用于易损斑块或与易损斑块相关的疾病的诊断、预防和治疗。

Description

用于靶向活化CD44分子的脂质体纳米载体递送系统、其制备方法和用途
相关申请的交叉引用
本申请要求2018年01月22日提交的第CN201810060265.9号中国发明专利申请的优先权，所述申请以引用的方式并入本文。
技术领域
本发明属于靶向给药技术领域，具体涉及一种用于靶向活化CD44分子，尤其是靶向易损斑块的纳米载体，尤其是脂质体纳米递送系统。本发明也涉及所述纳米载体，尤其是脂质体纳米递送系统的制备方法和用途，特别是在易损斑块或与易损斑块相关的疾病的诊断、预防和治疗中的用途。
背景技术
目前，以急性心肌梗死和心源性猝死为主的急性心血管事件已成为危害人类健康的头号杀手。据统计，全世界每年约有2千万人死于急性心血管事件。在中国，情况同样不容乐观，每年有超过70万人死于急性心肌梗死和心源性猝死，这已经成为严重威胁我国居民健康的最重要疾病之一。研究表明，大部分的急性心肌梗死和心源性猝死均是由动脉粥样硬化斑块引起的。自上世纪70年代以来，人们一直在探索慢性动脉粥样硬化斑块导致急性冠脉综合征(ACS)及脑卒中的发生过程及机制。
1989年，Muller及其团队(Circadian variation and triggers of onset of acute cardiovascular disease.Circulation.1989；79(4):733-43)提出了“易损斑块”的概念，认为此类斑块是导致大多数急性心脑血管事件的根本原因。易损斑块(vulnerable plaque，又称为“不稳定斑块(unstable plaque)”)是指具有血栓形成倾向或极有可能快速进展成为“罪犯斑块”的动脉粥样硬化斑块，主要包括破裂斑块、侵蚀性斑块和部分钙化结节性病变。大量的研究表明，大部分的急性心肌梗死及脑卒中是由于轻、中度狭窄的易损斑块破裂，继发血栓形成所致。Naghavi及其团队(New developments in the detection of vulnerable plaque.Curr Atheroscler Rep.2001；3(2):125-35)等给出了易损斑块的组织学定义和标准。主要的标准包括活动性炎症、薄的纤维帽和大的脂质核心、内皮剥脱伴表面血小板聚集、斑块有裂隙或损伤以及严重的狭窄。次要的标准包括表面钙化斑、黄色有光泽的斑块、斑块内出血和正性重构。因此，对于易损斑块而言，早期干预至关重要。但是由于一般情况下易损斑块所导致的血管狭窄程度并不高，很多患者没有前驱症状，导致临床上很难进行早期诊断，使得其危险性极高。因此，如何尽早准确的识别和诊断易损斑块，进行有效的干预成为预防及治疗急性心肌梗死中亟待解决的问题。
目前常用于易损斑块诊断的技术主要包括冠脉造影、血管内超声(IVUS)、激光相干断层显像(OCT)等技术，但这些技术均属于有创性的检查，并且诊断分辨率和准确性不高，同时这些诊断技术费用昂贵，也在一定程度上限制了临床上的普及。因此，目前急需针对易损斑块的无创诊断技术和制剂。
另外，目前治疗易损斑块的方法主要是全身给药，例如口服他汀类药物(羟甲基戊二酰辅酶A(HMG-CoA)还原酶抑制剂)、阿司匹林、基质金属蛋白酶(MMPs)抑制剂和/或贝特类药物等。这些药物通过调节全身血脂、对抗炎症、抑制蛋白酶和血小板生成等来减少斑块内的脂质，改善血管重构等，从而起到稳定斑块的作用。然而，临床应用中发现目前用于治疗易损斑块的药物的治疗效果并不理想。例如，临床常用的他汀类药物的口服给药生物利用度比较低，如辛伐他汀为＜5％，阿托伐他汀为约12％，瑞舒伐他汀为约20％。动物实验也证实，当他汀类药物的剂量增加到1mg/kg以上时才可以起到增加纤维帽厚度和减少斑块体积的作用，这就使得他汀类药物的口服给药的稳定性及逆转斑块的效果遭遇了瓶颈。目前临床试验也已经证实，口服他汀类药物治疗易损斑块需要采用强化大剂量才能具有稳定易损斑块的作用，而全身大剂量使用他汀类药物治疗也存在严重副作用(例如肝功能异常、横纹肌溶解、II型糖尿病等)发生率升高的风险。
对于现有的全身性给药而言，药物在进入体内后通常仅有极少一部分有效成分能够真正作用于病变部位。这是制约药物疗效，并导致药物毒副作用的根本原因。靶向给药系统是指具有靶向给药能力的给药系统。在经某种途径给药以后，靶向给药系统所包含的药物会通过带有靶向探针的载体特异性地富集于靶部位。靶向给药系统能够使药物瞄准特定的病变部位，并在目标病变部位释放有效成分。因此，靶向给药系统可以使药物在目标病变部位形成相对较高的浓度，并减少血液循环中的药量，从而在提高药效的同时抑制毒副作用，减少对正常组织和细胞的伤害。
在易损斑块的诊断和治疗领域中，也存在一些利用靶向配体修饰纳米载体来诊断易损斑块的技术。然而，此类靶向易损斑块的靶向探针在临床实际应用中的主要问题在于这些制剂的靶向位点的特异性不足。例如，此类制剂的靶向位点大多选择巨噬细胞，但由于巨噬细胞可存在于身体各处，所以所述探针的靶向特异性不够理想。因此，靶向易损斑块的靶向制剂的研制中存在的难点在于发现易损斑块内的细胞中的具有显著靶向特异性的靶位。
CD44是一类黏附分子，广泛分布于淋巴细胞、单核细胞、内皮细胞等的表面。CD44分子的主要配体是透明质酸(hyaluronic acid，缩写为“HA”)。基于表达细胞的活化状态，可以将CD44分为相对静止状态(不能结合HA)、诱导活化状态(激活后可结合HA)和结构活跃状态(无需激活即可与HA结合)，而大多数正常细胞表面的CD44处于相对静止状态，从而不能与HA相结合。
继往大量研究表明CD44并不是具有显著靶向特异性的理想靶位。这是因为CD44在人体内广泛分布，尤其是大量存在于网状内皮丰富的器官表面上。因此，以CD44为靶位的靶向给药系统的研发中会遇到如下问题：如果靶位细胞表面的CD44与HA的亲和力不足以提供显著的特异性，那么此类靶向给药系统就不会存在特异性靶向性能。
因此，寻找易损斑块部位存在的特异性靶位以及适合于靶向易损斑块的靶向给药系统，由此开发能够特异性地靶向易损斑块，并同时能够实现药物的稳定持续释放的靶向 给药系统，已经成为医学领域中的一个亟待解决的技术问题。
迄今为止，对于易损斑块内主要存在的巨噬细胞、单核细胞、内皮细胞、淋巴细胞和平滑肌细胞的表面上的CD44的表达状态及其与HA的亲和力尚无任何报道，也不存在任何关于利用HA和CD44的相互作用以及易损斑块的特定微环境设计用于诊断或治疗易损斑块或与易损斑块相关的疾病的能够实现药物的稳定持续释放的靶向给药系统的现有技术。
发明内容
(1)发明概述
发明人发现，与正常细胞相比，易损斑块中的细胞诸如内皮细胞、巨噬细胞和平滑肌细胞等的表面的CD44会被易损斑块的微环境(诸如在炎症因子的影响下)所诱导活化，导致与HA的结合能力会骤然增强数十倍。这一发现提示，易损斑块处的细胞表面存在的大量活化的CD44分子为以HA为靶向配体的靶向给药系统提供了理想的靶位。为此，本发明提供了一种能够特异性地靶向活化的CD44分子，尤其是靶向易损斑块的靶向给药系统。
发明人还发现，负载CD44活化剂可以促使病灶细胞表面的CD44进一步活化，可以在短时间内放大CD44对HA的靶向亲和力，显著增加结合在细胞表面的靶向组合物浓度，这对于易损斑块的示踪诊断和治疗具有积极意义。为此，本发明所述的靶向给药系统可以负载CD44活化剂，其可以在短时间内显著增加示踪剂或治疗剂化合物的浓度以提高诊断分辨率或治疗效果。
发明人还发现，在易损斑块内，伴随CD44的高度活化与过表达，同时内源性大分子HA也受激大量生成，并与细胞表面CD44结合，促进巨噬细胞和淋巴细胞等在易损斑块内的聚集。此种在细胞表面结合CD44的内源性HA会形成药物进入的屏障，会降低药物的生物利用度。为此，本发明所述的靶向给药系统可以负载小分子透明质酸或能够与易损斑块处的细胞表面上的CD44分子特异性结合的透明质酸的衍生物，其通过与细胞表面的内源性HA的竞争性结合，解除内源性HA在细胞表面形成的屏障，有利于药物顺利进入病灶细胞内，显著提供治疗效果。
总而言之，本发明涉及如下方面：
本发明提供了一种用于靶向靶向活化的CD44分子的脂质体纳米载体递送系统。
本发明提供了一种用于靶向易损斑块的脂质体纳米载体递送系统。
本发明还提供了一种用于制备本发明所述的靶向易损斑块的脂质体纳米载体递送系统的方法。
本发明还提供了一种药物，其包含本发明所述的靶向易损斑块的纳米载体递送系统和药学上可接受的载体。
本发明还提供了一种诊断制剂，其包含本发明所述的靶向易损斑块的纳米载体递送系统。
本发明还提供了本发明所述的靶向易损斑块的纳米载体递送系统在制备用于预防和/或治疗易损斑块或与易损斑块相关的疾病的药物中的用途。
本发明还提供了本发明所述的靶向易损斑块的纳米载体递送系统在制备用于诊断易 损斑块或与易损斑块相关的疾病的诊断制剂中的用途。
本发明还提供了一种用于预防和/或治疗易损斑块或与易损斑块相关的疾病的方法，所述方法包括向需要其的对象施用本发明所述的靶向易损斑块的纳米载体递送系统。
本发明还提供了一种用于诊断易损斑块或与易损斑块相关的疾病的方法，所述方法包括向需要其的对象施用本发明所述的靶向易损斑块的纳米载体递送系统。
本发明技术方案的具体实施方式及其含义将在下文中进行详细说明。
(2)技术术语及其含义
本文中所提及的术语具有以下含义：
“易损斑块”又称“不稳定斑块”，是指具有血栓形成倾向或极有可能快速进展成为“罪犯斑块”的动脉粥样硬化斑块，主要包括破裂斑块、侵蚀性斑块和部分钙化结节性病变。大量的研究表明，大部分的急性心肌梗死及脑卒中是由于轻、中度狭窄的易损斑块破裂，继发血栓形成所致。易损斑块的组织学表现包括活动性炎症、薄的纤维帽和大的脂质核心、内皮剥脱伴表面血小板聚集、斑块有裂隙或损伤以及严重的狭窄，以及表面钙化斑、黄色有光泽的斑块、斑块内出血和正性重构。
“与易损斑块相关的疾病”主要是指疾病的发生和发展过程中与“易损斑块”相关、以为“易损斑块”特征、由“易损斑块”引起或继发于“易损斑块”的疾病。“与易损斑块相关的疾病”主要包括动脉粥样硬化症、冠状动脉粥样硬化性心脏病(包括急性冠脉综合征、无症状心肌缺血-隐匿性冠心病、心绞痛、心肌梗死、缺血性心脏病、猝死、支架内再狭窄)、脑动脉粥样硬化症(包括脑卒中)、外周血管动脉粥样硬化症(包括闭塞性周围动脉粥样硬化、视网膜动脉粥样硬化症、颈动脉粥样硬化症、肾动脉粥样硬化症、下肢动脉粥样硬化症、上肢动脉粥样硬化症、动脉粥样硬化性阳痿)、主动脉夹层、血管瘤、血栓栓塞、心力衰竭和心源性休克等疾病。
“靶向给药系统”是指具有靶向给药能力的给药系统。在经某种途径给药以后，靶向给药系统所包含的药物会通过特殊载体或靶向弹头(例如，靶向配体)的作用特异性地富集于靶部位。目前已知的用于实现靶向给药的手段包括利用各种微粒给药系统的被动靶向性能、在微粒给药系统的表面进行化学修饰、利用一些特殊的理化性能、利用抗体介导靶向给药、利用配体介导靶向给药、利用前体药物靶向给药等。其中，利用配体介导靶向给药是利用某些器官和组织上的特定的受体可与其特异性的配体发生专一性结合的特点，将药物载体与配体结合，从而将药物导向特定的靶组织。
“脂质体载体”是一种类脂质双分子层药物载体，其将药物包封于类脂质双分子层内而形成微型泡囊体。也可为脂质双层纳米盘(bicelle)结构一般是有长链的磷脂和短链的磷脂或者表面活性剂自组装形成圆盘状物。长链脂质形成圆盘的平面，短链磷脂包围在圆盘的侧面边缘。二肉豆蔻酰磷脂酰胆碱(DMPC)常被用作长链磷脂成分，并且可以通过掺杂其他的具有相同链长度而不同头部基团的磷脂成分来改变bicelle的表面电荷以及实现其多功能性。而短链磷脂形成一个高曲率区域降低聚集体的边缘能量，从而起到稳定bicelle的作用。
“透明质酸(hyaluronic acid，缩写为“HA”)”是一种高分子的聚合物，分子式：(C14H21NO11)n。它是由单位D-葡萄糖醛酸及N-乙酰葡糖胺组成的高级多糖。D-葡萄糖醛酸及N-乙酰葡糖胺之间由β-1,3-配糖键相连，双糖单位之间由β-1,4-配糖键相连。透明 质酸以其独特的分子结构和理化性质在机体内显示出多种重要的生理功能，如润滑关节，调节血管壁的通透性，调节蛋白质，水电解质扩散及运转，促进创伤愈合等。尤为重要的是，透明质酸具有特殊的保水作用，是目前发现的自然界中保湿性最好的物质。
“透明质酸的衍生物”在本文中是指任何能够保留透明质酸与易损斑块处的细胞表面上的CD44分子的特异性结合能力的透明质酸的衍生物，包括但不限于透明质酸的药学上可接受的盐、低级烷基(含有1-6个碳原子的烷基)酯、在体内能够经水解或其它方式形成透明质酸的前体药物等。判断某种物质是否是“透明质酸的衍生物”可以通过测定该物质与易损斑块处的细胞表面上的CD44分子的特异性结合能力来实现，这属于本领域技术人员的技能范围之内。
“CD44分子”是一类广泛地表达于淋巴细胞、单核细胞、内皮细胞等细胞的细胞膜上的跨膜蛋白多糖黏附分子，由胞外区段、跨膜区段和胞内区段等三个区段构成。CD44分子可介导多种细胞与细胞、细胞与细胞外基质之间的相互作用，参与体内的多种信号的传导，从而改变细胞的生物学功能。CD44分子的主要配体是透明质酸，它与透明质酸之间的受体-配体结合决定了细胞在细胞外基质中的黏附和/或迁移。此外，CD44分子还参与透明质酸的代谢。
“约”代表在其后面给出的数值的±5％的范围内的所有值构成的集合。
(3)发明详述
本发明的第一方面提供了一种用于靶向活化的CD44分子的脂质体纳米载体递送系统，所述纳米载体的表面部分地被靶向配体修饰，所述靶向配体是能与活化的CD44分子特异性结合的配体。
本发明的第二方面提供了一种用于靶向易损斑块的脂质体纳米载体递送系统，所述纳米载体的表面部分地被靶向配体修饰，所述靶向配体是能与易损斑块处的细胞表面上的CD44分子特异性结合的配体。纳米载体表面还可以进行其他修饰，起到更好的效果。在载体表面修饰PEG，可以起到长循环的效果，延长药物的半衰期；在载体表面修饰穿膜肽，自身肽SEP，或者双重配体同时修饰，都可以起到放大药效的作用。
根据本发明第一方面或第二方面的纳米载体递送系统，其中，所述脂质体选自脂质双层纳米盘(bicelle)，小单室脂质体、大单室脂质体、多室脂质体。“脂质体载体”是一种类脂质双分子层药物载体，其将药物包封于类脂质双分子层内、或亲水内腔中而形成微型泡囊，或圆盘结构。
脂质双层纳米盘(bicelle)可为结构一般是有长链的磷脂和短链的磷脂或者表面活性剂自组装形成的盘状物。长链脂质形成圆盘的平面，短链磷脂包围在圆盘的侧面边缘。二肉豆蔻酰磷脂酰胆碱(DMPC)常被用作长链磷脂成分，并且可以通过掺杂其他的具有相同链长度而不同头部基团的磷脂成分来改变bicelle的表面电荷以及实现其多功能性。而短链磷脂一边选为双-正-十七烷酰磷脂酰胆碱形成一个高曲率区域降低聚集体的边缘能量，从而起到稳定bicelle的作用。
根据本发明第一方面或第二方面的脂质体纳米载体递送系统，其中，所述靶向配体选自GAG、胶原、层黏连蛋白、纤黏连蛋白、选择蛋白、骨桥蛋白(OPN)以及单克隆抗体HI44a，HI313，A3D8，H90，IM7，或透明质酸或能够与易损斑块处的细胞表面上的CD44分子特异性结合的透明质酸的衍生物。
根据本发明第一方面或第二方面的纳米载体递送系统，其中，所述纳米载体负载有用于诊断、预防和/或治疗与出现CD44分子活化状况相关的疾病的物质。
根据本发明第一方面或第二方面的水凝胶纳米载体递送系统，其中，所述纳米载体负载有用于诊断、预防和/或治疗易损斑块或与易损斑块相关的疾病的物质；
在一个实施方案中，所述物质是用于诊断易损斑块或与易损斑块相关的疾病的物质；
在一个实施方案中，所述用于诊断易损斑块或与易损斑块相关的疾病的物质是示踪剂；
在一个实施方案中，所述示踪剂选自CT示踪剂，MRI示踪剂和核素示踪剂；
在一个实施方案中，所述CT示踪剂选自碘纳米造影剂、金纳米造影剂、氧化钽纳米造影剂、铋纳米造影剂、镧系纳米造影剂，或其他类似结构的示踪剂；更优选为碘化造影剂或纳米金，或其他类似结构的示踪剂；进一步优选为碘海醇、碘卡酸、碘佛醇、碘克沙醇、碘普罗胺、碘比醇、碘美普尔、碘帕醇、碘昔兰、醋碘苯酸、胆影酸、碘苯扎酸、碘甘卡酸、泛影酸、碘他拉酸钠、碘苯酯、碘番酸、碘阿芬酸、醋碘苯酸钠、碘多啥、丙碘酮、碘奥酮、碘曲仑、碘吡多、胆影酸葡甲胺、碘他拉酸、泛影葡胺、甲泛影酸、甲泛葡铵、碘化油或乙碘油，或其他类似结构的示踪剂，优选为纳米金；和/或
所述MRI示踪剂选自纵向弛豫造影剂和横向弛豫造影剂；更优选为顺磁性造影剂、铁磁性造影剂和超磁性造影剂；进一步优选为Gd-DTPA及其线型、环型多胺多羧类螯合物和锰的卟啉螯合物，大分子钆螯合物、生物大分子修饰的钆螯合物、叶酸修饰的钆螯合物、树状大分子显影剂、脂质体修饰的显影剂和含钆富勒烯，或其他类似结构的示踪剂；再优选为钆喷酸葡胺、钆特酸葡胺、钆贝葡胺、钆双胺、枸橼酸铁铵泡腾颗粒、顺磁性氧化铁(Fe3O4NPs)，或其他类似结构的示踪剂，优选为Fe3O4NPs；
所述核素示踪剂选自有碳14(14C)、碳13(13C)、磷32(32P)、硫35(35S)、碘131(131I)、氢3(3H)、锝99(99Tc)、氟18(18F)标记的氟代脱氧葡萄糖。
在一个实施方案中，所述物质是用于诊断、预防和/或治疗易损斑块或与易损斑块相关的疾病的药物、多肽、核酸和细胞因子中的一种或多种。
在一个实施方案中，所述物质是CD44活化剂；
在一个实施方案中，所述CD44活化剂是CD44抗体mAb或IL5、IL12、IL18、TNF-α、LPS；
在一个实施方案中，所述物质是小分子透明质酸或能够与易损斑块处的细胞表面上的CD44分子特异性结合的透明质酸的衍生物；
优选地，所述小分子透明质酸或能够与易损斑块处的细胞表面上的CD44分子特异性结合的透明质酸的衍生物的分子量范围为1-500KDa，优选为1-20KDa，更优选为2-10KDa。
在一个实施方案中，所述纳米载体同时负载有用于诊断、预防和/或治疗易损斑块或与易损斑块相关的疾病的物质和CD44活化剂；
优选地，所述纳米载体同时负载有用于预防和/或治疗易损斑块或与易损斑块相关的疾病的物质和透明质酸或能够与易损斑块处的细胞表面上的CD44分子特异性结合的透明质酸的衍生物；
更优选地，所述纳米载体同时负载有用于诊断易损斑块或与易损斑块相关的疾病的 物质、用于预防和/或治疗易损斑块或与易损斑块相关的疾病的物质、任选的CD44活化剂和任选的透明质酸或能够与易损斑块处的细胞表面上的CD44分子特异性结合的透明质酸的衍生物。
在一个实施方案中，所述物质是用于预防和/或治疗易损斑块或与易损斑块相关的疾病的物质；
优选地，所述用于预防和/或治疗易损斑块或与易损斑块相关的疾病的物质选自他汀类药物、贝特类药物、抗血小板药物、PCSK9抑制剂、抗凝药物、血管紧张素转换酶抑制剂(ACEI)、钙离子拮抗剂、MMPs抑制剂、β受体阻滞剂，糖皮质激素或其他的抗炎物质如IL-1抗体canakinumab，以及它们的药学上可接受的盐中的一种或多种，包括这些种类药物或物质的活性制剂，以及内源性的抗炎细胞因子比如白细胞介素10(IL-10)；
更优选地，所述用于预防和/或治疗易损斑块或与易损斑块相关的疾病的物质选自洛伐他汀、阿托伐他汀、瑞舒伐他汀、辛伐他汀、氟伐他汀、匹伐他汀、普伐他汀，苯扎贝特、环丙贝特、氯贝特、吉非贝齐、非诺贝特、普罗布考，抗PCSK9抗体如evolocumab、alirocumab、bococizumab、RG7652、LY3015014和LGT-209，或adnectin如BMS-962476，反义RNAi寡核苷酸如ALN-PCSsc，核酸如microRNA-33a、microRNA-27a/b、microRNA-106b、microRNA-302、microRNA-758、microRNA-10b、microRNA-19b、microRNA-26、microRNA-93、microRNA-128-2、microRNA-144、microRNA-145反义链以及它们的核酸类似物如锁核酸，阿司匹林、阿西美辛、曲克芦丁、双嘧达莫、西洛他唑、盐酸噻氯匹定、奥扎格雷钠、氯吡格雷、普拉格雷、西洛他唑、贝列前素钠、替格瑞洛、坎格瑞洛、替罗非班、依替巴肽、阿昔单抗、普通肝素、克赛、速碧林、黄达肝葵钠、华法林、达比加群、利伐沙班、阿哌沙班、依度沙班、比伐卢定、依诺肝素、替他肝素、阿地肝素、双香豆素、硝酸香豆素、枸杞酸钠、水蛭素、阿加曲班，贝那普利、卡托普利、依那普利、培多普利、福辛普利、赖诺普利、莫昔普利、西拉普利、培哚普利、喹那普利、雷米普利、群多普利、坎地沙坦，依普罗沙坦、厄贝沙坦、氯沙坦、替米沙坦、缬沙坦、奥美沙坦、他索沙坦、硝苯地平、尼卡地平、尼群地平、氨氯地平、尼莫地平、尼索地平、尼伐地平、伊拉地平、非洛地平、拉西地平、地尔硫卓、维拉帕米、氯己定、米诺环素、MMI-166、美托洛尔、阿替洛尔、比索洛尔、普萘洛尔、卡维地络、巴马司他、马立马司他、普啉司他、BMS-279251、BAY 12-9566、TAA211、AAJ996A、nacetrapib、evacetrapib、Torcetrapib和Dalcetrapib，泼尼松、甲泼尼松、倍他米松、丙酸倍氯米松、得宝松、泼尼松龙、氢化可的松、地塞米松或其他的抗炎物质如IL-1抗体canakinumab)，以及它们的药效片段或药学上可接受的盐中的一种或多种，以及它们的药学上可接受的盐中的一种或多种，包括这些种类药物的活性结构片段，以及内源性的抗炎细胞因子比如白细胞介素10(IL-10)。
本发明的第三方面提供了一种用于制备第一方面或第二方面所述的用于靶向易损斑块的纳米递送系统的方法，所述方法包括以下步骤：
(1)将适量的磷脂分子溶解于合适的有机溶剂中，通过薄膜水化法制备脂质体纳米载体，对于极性较差的药物分子，需要在这一步和磷脂分子共同成膜。
(2)任选地向步骤(1)所得纳米载体递送系统中加入任选含有水溶性的用于诊断、预防和/或治疗易损斑块或与易损斑块相关的疾病的物质的水性介质，形成粗制悬浮液；
(3)将靶向配体溶解于合适的缓冲溶液溶剂中，将步骤(2)所得的载体分子加入靶向配体溶液中进行反应，得到所述纳米载体递送系统；
(4)任选地通过透析法除去步骤(3)中得到的所述粗制悬浮液中所含有的未负载的用于诊断、预防和/或治疗易损斑块或与易损斑块相关的疾病的物质，得到负载的纳米递送系统。
本发明的第四方面提供了一种药物，所述药物包含第一方面或第二方面所述的纳米载体递送系统以及药学上可接受的载体。
本发明的第五方面提供了一种诊断制剂，所述诊断制剂包含第一方面或第二方面所述的纳米载体递送系统。
本发明的第六方面提供了第一方面或第二方面所述的纳米载体递送系统、第四方面所述的药物、或第五方面所述的诊断制剂在制备用于预防和/或治疗与出现CD44分子活化状况相关的疾病的药物中的用途。
本发明的第七方面提供了第一方面或第二方面所述的纳米载体递送系统、第四方面所述的药物、或第五方面所述的诊断制剂在制备用于预防和/或治疗与易损斑块或与易损斑块相关的疾病的药物和/或诊断制剂中的用途。
根据本发明第七方面的用途，所述易损斑块选自破裂斑块、侵蚀性斑块和部分钙化结节性病变中的一种或多种；
优选地，所述与易损斑块相关的疾病选自动脉粥样硬化症、冠状动脉粥样硬化性心脏病(包括急性冠脉综合征、无症状心肌缺血-隐匿性冠心病、心绞痛、心肌梗死、缺血性心脏病、猝死、支架内再狭窄)、脑动脉粥样硬化症(包括脑卒中)、外周血管动脉粥样硬化症(包括闭塞性周围动脉粥样硬化、视网膜动脉粥样硬化症、颈动脉粥样硬化症、肾动脉粥样硬化症、下肢动脉粥样硬化症、上肢动脉粥样硬化症、动脉粥样硬化性阳痿)、主动脉夹层、血管瘤、血栓栓塞、心力衰竭和心源性休克中的一种或多种。
本发明的第八方面提供了一种用于预防和/或治疗与出现CD44分子活化状况相关的疾病的方法，所述方法包括：对有需要的受试者给予第一方面或第二方面所述的纳米载体递送系统、第四方面所述的药物、或第五方面所述的诊断制剂。
本发明的第九方面提供了一种用于预防、诊断和/或治疗易损斑块或与易损斑块相关的疾病的方法，所述方法包括：对有需要的受试者给予第一方面或第二方面所述的纳米载体递送系统、第四方面所述的药物、或第五方面所述的诊断制剂。
优选地，所述易损斑块选自破裂斑块、侵蚀性斑块和部分钙化结节性病变中的一种或多种。
更优选地，所述与易损斑块相关的疾病选自动脉粥样硬化症、冠状动脉粥样硬化性心脏病(包括急性冠脉综合征、无症状心肌缺血-隐匿性冠心病、心绞痛、心肌梗死、缺血性心脏病、猝死、支架内再狭窄)、脑动脉粥样硬化症(包括脑卒中)、外周血管动脉粥样硬化症(包括闭塞性周围动脉粥样硬化、视网膜动脉粥样硬化症、颈动脉粥样硬化症、肾动脉粥样硬化症、下肢动脉粥样硬化症、上肢动脉粥样硬化症、动脉粥样硬化性阳痿)、主动脉夹层、血管瘤、血栓栓塞、心力衰竭和心源性休克中的一种或多种。
本发明的第十方面提供了一种用于诊断与出现CD44分子活化状况相关的疾病的方法，所述方法包括包括：对有需要的受试者给予第一方面或第二方面所述的纳米载体递 送系统、第四方面所述的药物、或第五方面所述的诊断制剂。
总而言之，本发明所述的纳米载体递送系统，对于出现CD44分子活化状况的疾病而言，具有如下优点：
1)本发明的纳米载体递送系统能够特异性结合至活化的CD44分子，并能够实现药物的稳定持续释放。
2)易损斑块中的细胞表面CD44被细胞外基质微环境所诱导活化，大量过表达，并且CD44-HA的亲和力显著提高，使得易损斑块内的CD44与HA的相互作用具有极为显著的亲和特异性。由此，易损斑块内的CD44构成了本发明所述的靶向易损斑块的纳米载体递送系统的优良靶点。
3)本发明所述的靶向易损斑块的纳米载体递送系统能够主动靶向进入易损斑块内并与病灶细胞结合。因此，该递送系统可以实现所负载的物质在病灶处的持续释放，显著增加并持续保持病灶区域的物质浓度，从而提高该递送系统的诊断或治疗效果。
4)本发明所述的靶向易损斑块的纳米载体递送系统还可以负载促CD44活化物质即CD44活化剂例如IL5、IL12、IL18、TNF-α、LPS。负载CD44活化剂可以促使病灶细胞表面的CD44进一步活化，可以在短时间内放大CD44对透明质酸的靶向亲和力，显著增加结合在细胞表面的靶向纳米载体组合物浓度，这对于易损斑块的示踪诊断和治疗具有积极意义，因为其可以在短时间内显著增加示踪剂或治疗剂化合物的浓度以提高诊断分辨率或治疗效果。
附图说明
为了使本发明的内容得到更充分的理解，下面通过本发明的具体实施例并结合附图，对本发明作进一步详细地说明，其中：
图1为实施例1中LP1-(R)-HA的电镜图。
图2为实施例1中LP1-(R)-HA的红外光谱图。
图3为实施例2中LP1-(R)-SP的表征图。
图4为实施例3中LP1-(R)-HA/Tat的表征图。
图5为实施例4中LP2-(At)-HA的表征图。
图6为实施例5中LP2-(At)-SEP/IM7的表征图。
图7为实施例6中LP2-(At/miRNA-33a)-IM7的表征图。
图8为实施例7中LP2-(AuNP/R)-OPN的表征图。
图9为实施例8中LP1-(Fe3O4/DXMS)-HI44a的表征图。
图10为实施例9中LP1-(Fe3O4/IL-10)-HI44a的表征图。
图11为实施例10中LP1-(Asp/Clo)-Col的表征图。
图12为实施例11中LP1-(F-FDG)-OPN的表征图。
图13为试验例1中长期放置对粒径稳定性的影响。
图14为试验例1中长期放置对包封率的影响。
图15为试验例1中脂质体载体的体外累积释放率。
图16为试验例2中构建的小鼠动脉粥样硬化易损斑块模型的核磁共振成像图。
图17为模型小鼠的正常动脉血管壁内皮细胞和动脉易损斑块处内皮细胞表面的CD44含量测定结果(以半定量积分表示)图。
图18为模型小鼠的正常动脉血管壁内皮细胞和动脉易损斑块处内皮细胞表面的CD44与HA的结合力测定结果(以结合力积分表示)图。
图19为模型小鼠的斑块外巨噬细胞和动脉易损斑块内巨噬细胞表面的CD44与HA的结合力测定结果(以结合力积分表示)图。
图20为本发明的LP1-(R)-HA，LP1-(R)-SP，LP1-(R)-HA/Tat纳米递送系统对模型小鼠的颈动脉易损斑块的治疗效果图。
图21为LP2-(At)-HA，LP2-(At)-SEP/IM7，LP2-(At/miRNA-33a)-IM7纳米递送系统对模型小鼠的颈动脉易损斑块的治疗效果图。
图22为LP2-(AuNP/R)-OPN及其他CT示踪剂纳米递送系统对模型小鼠的颈动脉易损斑块的体内示踪效果图。
图23为LP2-(AuNP/R)-OPN纳米递送系统对模型小鼠的颈动脉易损斑块的治疗效果图。
图24为LP1-(Fe3O4/DXMS)-HI44a，LP1-(Fe3O4/IL-10)-HI44a及其他MRI示踪剂纳米递送系统对模型小鼠的颈动脉易损斑块的体内示踪效果图。
图25为LP1-(Fe3O4/DXMS)-HI44a，LP1-(Fe3O4/IL-10)-HI44a纳米递送系统对模型小鼠的颈动脉易损斑块的治疗效果图。
图26为LP1-(Asp/Clo)-Col纳米递送系统对模型小鼠动脉易损斑块破裂的治疗效果图。
图27为LP1-(F-FDG)-OPN核素示踪剂纳米递送系统对模型小鼠的颈动脉易损斑块的体内示踪效果图。
为了进一步理解本发明，下面结合实施例对本发明的具体实施方案进行详细描述。但是应当理解，这些描述的目的只是为进一步说明本发明的特征和优点，而不构成对本发明的权利要求的任何限制。
具体实施方式
下面通过具体的实施例进一步说明本发明，但是，应当理解为，这些实施例仅仅是用于更详细具体地说明之用，而不应理解为用于以任何形式限制本发明。
本部分对本发明试验中所使用到的材料以及试验方法进行一般性的描述。虽然为实现本发明目的所使用的许多材料和操作方法是本领域公知的，但是本发明仍然在此作尽可能详细描述。本领域技术人员清楚，在上下文中，如果未特别说明，本发明所用材料和操作方法是本领域公知的。
实施例1使用透明质酸(HA)修饰的负载瑞舒伐他汀(R)脂质体纳米囊泡(LP1-(R)-HA)的制备
在本实施例中，采用薄膜分散法制备负载治疗剂的脂质体纳米囊泡LP1-(R)-HA。上述脂质体递送系统的纳米囊泡的表面均部分地被靶向配体透明质酸(缩写为“HA”)修饰，并且均负载用于预防和/或治疗易损斑块或与易损斑块相关的疾病的物质瑞舒伐他汀(用 缩写“R”表示)
(1)LP1-(R)脂质体纳米囊泡悬浮液的制备：
称取4mg二硬脂酰磷脂酰胆碱(DSPC)、胆固醇、二肉豆蔻酰基磷脂酰乙醇胺(DMPE)(摩尔比为4:1:1)，加入药物瑞舒伐他汀(R)(药物总量与脂质摩尔比为1:10)于10mL氯仿溶解。通过缓慢旋转蒸发(65℃水浴，90r/min，30min)除去有机溶剂，从而在容器壁上形成薄膜。放在50℃的恒温水浴锅中使薄膜充分水化，形成粗制脂质体纳米囊泡悬浮液。将粗制脂质体纳米囊泡悬浮液水浴超声，最后用探头超声仪超声处理3min(振幅20，间隔为3s)，将精制脂质体纳米囊泡悬浮液中未包封的药物用葡聚糖凝胶柱G-100除去。
(2)透明质酸(“HA”)的活化和偶联：
将1g HA(分子量为约100KDa)充分溶解于超纯水中，加入0.1g 1-(3-二甲氨基丙基)-3-乙基碳二亚胺盐酸盐(EDC.HCl)和0.12g N-羟基硫代琥珀酰亚胺(sulfo-NHS)偶联剂活化羧基。在室温搅拌反应1小时后，加入无水乙醇沉淀活化的HA。将沉淀过滤、用乙醇洗涤并真空干燥，得到活化的HA。将其配置成为0.1mg mL -1的水溶液，吸取0.2mL溶液溶于上面的步骤(1)中得到的脂质体纳米囊泡浮液中，使活化的HA中的活化的羧基和脂质体纳米囊泡的脂质双分子层中掺杂的DSPE分子具有的氨基通过形成酰胺键实现偶联，从而得到负载治疗剂的脂质体递送系统LP1-(R)-HA。图1为LP1-(R)-HA的电镜图。图2为LP1-(R)-HA的红外光谱图。
实施例2使用选择蛋白(SP)修饰的负载瑞舒伐他汀(R)脂质体纳米囊泡(LP1-(R)-SP)的制备
在本实施例中，采用薄膜分散法制备负载治疗剂的脂质体纳米囊泡LP1-(R)-SP。上述脂质体递送系统的纳米囊泡的表面均部分地被靶向配体选择蛋白(缩写为“SP”)修饰，并且均负载用于预防和/或治疗易损斑块或与易损斑块相关的疾病的物质瑞舒伐他汀(用缩写“R”表示)。
(1)脂质体纳米囊泡LP1-(R)的制备
按照实施例1方法制备脂质体纳米纳米囊泡LP1-(R)。
(2)选择蛋白(SP)的活化和偶联：
将1mg SP充分溶解于超纯水中，加入0.5mg 1-(3-二甲氨基丙基)-3-乙基碳二亚胺盐酸盐(EDC.HCl)和0.5mg N-羟基硫代琥珀酰亚胺(sulfo-NHS)偶联剂活化羧基。在室温搅拌反应1小时后，超滤纯化活化的蛋白质，并将其溶于上面的步骤(1)中得到的脂质体悬浮液中，使活化的SP中的活化的羧基和脂质体的脂质双分子层中掺杂的DMPE分子具有的氨基通过形成酰胺键实现偶联，从而得到负载治疗剂的脂质体递送系统LP1-(R)-SP。图3为LP1-(R)-SP的表征图。
实施例3使用透明质酸(HA)和穿膜肽(Tat)同时修饰的负载瑞舒伐他汀(R)脂质体纳米囊泡(LP1-(R)-HA/Tat)的制备
在本实施例中，采用薄膜分散法制备负载治疗剂的脂质体纳米囊泡LP1-(R)-HA/Tat。上述脂质体递送系统的纳米囊泡的表面均部分地被靶向配体透明质酸(缩写为“HA”)和穿 膜肽(Tat)同时修饰，并且均负载用于预防和/或治疗易损斑块或与易损斑块相关的疾病的物质瑞舒伐他汀(用缩写“R”表示)。
3.1脂质体递送系统的制备
按照实施例1方法制备脂质体纳米囊泡LP1-(R)。
3.2透明质酸(HA)和穿膜肽(Tat)的活化和偶联：
将10mg HA(分子量为约10KDa)充分溶解于超纯水中，加入5mg 1-(3-二甲氨基丙基)-3-乙基碳二亚胺盐酸盐(EDC.HCl)和5mg N-羟基硫代琥珀酰亚胺(sulfo-NHS)偶联剂活化羧基。在室温搅拌反应1小时后，加入无水乙醇沉淀活化的HA。将沉淀过滤、用乙醇洗涤并真空干燥，得到活化的HA。将其配置成为1mg mL-1的水溶液。
将1mg Tat肽充分溶解于PBS缓冲溶液中，加入0.1g 1-(3-二甲氨基丙基)-3-乙基碳二亚胺盐酸盐(EDC.HCl)和0.12g N-羟基硫代琥珀酰亚胺(sulfo-NHS)偶联剂活化羧基。在室温搅拌反应1小时后，超滤纯化除去未反应的有机小分子。将活化后的Tat配置成为1mg mL-1的水溶液。
吸取1mL HA溶液和0.5mL Tat溶液溶于纯化的脂质体纳米囊泡LP1-(R)溶液中，使活化的HA和Tat中的活化的羧基和脂质体囊泡的脂质双分子层中掺杂的DMPE分子具有的氨基通过形成酰胺键实现偶联，实现HA和Tat在LP1-(R)上的双重偶联，得到靶向识别纳米载体LP1-(R)-HA/Tat。图4为LP1-(R)-HA/Tat的红外表征图。
实施例4使用透明质酸(HA)和PEG同时修饰的负载阿托伐他汀(At)脂质体纳米盘(LP2-(At)-HA)的制备
(1)负载阿托伐他汀脂质体纳米盘LP2-(At)的制备：
称取4mg二肉豆蔻酰磷脂酰胆碱(DMPC)、短链的双-正-十七烷酰磷脂酰胆碱(DHPC)，二肉豆蔻酰基磷脂酰乙醇胺(DMPE)按摩尔比为7:2:1投料，加入药物阿托伐他汀At(药脂摩尔比为1:10)于10mL氯仿溶解。通过缓慢旋转蒸发(65℃水浴，90r/min，30min)除去有机溶剂，从而在容器壁上形成薄膜。向圆底烧瓶中加入10mL的水溶液(浓度为1.0mg/mL)，将烧瓶放在50℃的恒温水浴锅中使薄膜充分水化，形成粗制脂质体纳米盘悬浮液。将粗制脂质体纳米盘悬浮液水浴超声，最后用探头超声仪超声处理3min(振幅20，间隔为3s)，其中未包封的药物用葡聚糖凝胶柱G-100除去。
(2)透明质酸(“HA”)的活化和偶联：
将1g HA(分子量为约100KDa)充分溶解于超纯水中，加入0.1g 1-(3-二甲氨基丙基)-3-乙基碳二亚胺盐酸盐(EDC.HCl)和0.12g N-羟基硫代琥珀酰亚胺(sulfo-NHS)偶联剂活化羧基。在室温搅拌反应1小时后，加入无水乙醇沉淀活化的HA。将沉淀过滤、用乙醇洗涤并真空干燥，得到活化的HA。将其配置成为0.1mg mL-1的水溶液，吸取0.2mL溶液溶于上面的步骤(1)中得到的脂质体纳米盘悬浮液中，使活化的HA中的活化的羧基和PEG-NH 2(分子量1000)中的氨基、脂质体纳米盘的脂质双分子层中掺杂的DMPE分子具有的氨基通过形成酰胺键实现三者的偶联，从而得到负载治疗剂的脂质体递送系统LP2-(At)-HA。图5为LP2-(At)-HA的红外表征图。若无需修饰PEG，可将上述加入PEG-NH 2的环节省去，得到未修饰PEG的LP2-(At)-HA。
实施例5使用自身肽(SEP)和单克隆抗体IM7修饰的负载阿托伐他汀(At)脂质体纳米盘(LP2-(At)-SEP/IM7)的制备
5.1负载阿托伐他汀(At)脂质体纳米盘悬浮液的制备：
按照实施例4方法制备负载阿托伐他汀(At)脂质体纳米盘。
5.2 SEP或IM7的活化和偶联：
将1mg SEP充分溶解于超纯水中，加入0.5mg 1-(3-二甲氨基丙基)-3-乙基碳二亚胺盐酸盐(EDC.HCl)和0.5mg N-羟基硫代琥珀酰亚胺(sulfo-NHS)偶联剂活化羧基。在室温搅拌反应1小时后，超滤离心纯化获得活化的SEP。将1mg IM7充分溶解于超纯水中，加入0.1mg 1-(3-二甲氨基丙基)-3-乙基碳二亚胺盐酸盐(EDC.HCl)和0.1mg N-羟基硫代琥珀酰亚胺(sulfo-NHS)偶联剂活化羧基，超滤离心纯化获得活化的IM7。
将上述活化的SEP或IM7溶液溶于纯化的LP2-(At)溶液中，实现SEP/IM7在LP2-(At)上的双重偶联，得到靶向识别脂质体纳米盘LP2-(At)-SEP/IM7。图6为LP2-(At)-SEP/IM7的表征图。若无需修饰SEP，可将上述SEP活化和偶联的环节省去，得到未修饰SEP的LP2-(At)-IM7。
实施例6使用单克隆抗体IM7修饰的负载阿托伐他汀和微小RNA(miRNA-33a)脂质体纳米盘(LP2-(At/miRNA-33a)-IM7的制备
6.1负载阿托伐他汀(At)和微小RNA(miRNA-33a)脂质体纳米盘的制备：
称取4mgDOTAP、短链的双-正-十七烷酰磷脂酰胆碱(DHPC)，二肉豆蔻酰基磷脂酰乙醇胺(DMPE)按摩尔比为7:2:1投料，加入药物阿托伐他汀(药脂摩尔比为1:10)于10mL氯仿溶解。通过缓慢旋转蒸发(65℃水浴，90r/min，30min)除去有机溶剂，从而在容器壁上形成薄膜。向圆底烧瓶中加入10mL的水溶液(浓度为1.0mg/mL)，将烧瓶放在50℃的恒温水浴锅中使薄膜充分水化，形成粗制脂质体纳米盘悬浮液。将粗制脂质体纳米盘悬浮液水浴超声，最后用探头超声仪超声处理3min(振幅20，间隔为3s)，即精制脂质体盘悬浮液。将精制脂质体盘悬浮液中未包封的阿托伐他汀用葡聚糖凝胶柱G-100除去。滤液浓缩后加入一定量的微小RNA(miRNA-33a)，孵育2小时以促进其在纳米盘表面的结合，产品置于4℃下低温保存待用。
将1mg IM7充分溶解于超纯水中，加入0.5mg 1-(3-二甲氨基丙基)-3-乙基碳二亚胺盐酸盐(EDC.HCl)和0.5mg N-羟基硫代琥珀酰亚胺(sulfo-NHS)偶联剂活化羧基，超滤离心纯化获得活化的sulfo-NHS-IM7。将其溶于纯化的LP2-(At/miRNA-33a)溶液中，实现IM7在LP2-(At/miRNA-33a)上的双重偶联，得到靶向识别纳米载体LP2-(At/miRNA-33a)-IM7纳米盘。图7为LP2-(At/miRNA-33a)-IM7的红外表征图。
实施例7使用骨桥蛋白(OPN)修饰的负载瑞舒伐他汀(R)/金纳米颗粒(AuNP)脂质体纳米盘(LP2-(AuNP/R)-OPN)的制备
7.1制备金纳米颗粒(AuNP)
配置100mL 1mM HAuCl 4水溶液，加热至沸腾，在剧烈搅拌条件下加入1mL新制备0.1M硼氢化钠，制得AuNPs，通过超滤方法纯化溶液，浓缩溶液制得1mM AuNPs。
7.2负载瑞舒伐他汀(R)和金纳米颗粒(AuNP)的脂质体纳米盘LP2-(AuNP/R)制 备
称取4mg二肉豆蔻酰磷脂酰胆碱(DMPC)、短链的双-正-十七烷酰磷脂酰胆碱(DHPC)，二肉豆蔻酰基磷脂酰乙醇胺(DMPE)按摩尔比为7:2:1投料，加入药物瑞舒伐他汀(R)(药脂摩尔比为1:10)于10mL氯仿溶解。通过缓慢旋转蒸发(65℃水浴，90r/min，30min)除去有机溶剂，从而在容器壁上形成薄膜。并将烧瓶放在50℃的恒温水浴锅中使薄膜充分水化30min，加入1mL纯化的AuNPs(1mM)水溶液。将粗制脂质体纳米盘悬浮液水浴超声，最后用探头超声仪超声处理3min(振幅20，间隔为3s)，即精制脂质体纳米盘悬浮液。将精制脂质体纳米盘悬浮液中未包封的瑞舒伐他汀和AuNPs用葡聚糖凝胶柱G-100除去。
7.3制备骨桥蛋白(OPN)修饰的负载AuNP/R的脂质体纳米盘(LP2-(AuNP/R)-OPN)
将1mg OPN充分溶解于超纯水中，加入0.5mg 1-(3-二甲氨基丙基)-3-乙基碳二亚胺盐酸盐(EDC.HCl)和0.5mgN-羟基硫代琥珀酰亚胺(sulfo-NHS)偶联剂活化羧基。在室温搅拌反应1小时后，超滤离心纯化获得活化的OPN。吸取1.0mL OPN溶液溶于纯化的LP2-(AuNP/R)溶液中，实现OPN在LP2-(AuNP/R)上的偶联。图8为实施例7中LP2-(AuNP/R)-OPN的红外表征图。
替换原料，采用以上类似的制备方法本发明人还成功制备靶向CT示踪剂LP2-(碘普罗胺)-OPN，LP2-(碘克沙醇)-OPN和LP2-(碘氟醇)-OPN。
实施例8使用单克隆抗体(HI44a)修饰的负载地塞米松(DXMS)和磁性铁纳米颗粒(Fe3O4NPs)脂质体纳米囊泡LP1-(Fe3O4/DXMS)-HI44a的制备
8.1制备磁性磁性铁纳米颗粒(Fe3O4NPs)
配置100mL 10mM三氯化铁(FeCl3)水溶液，剧烈搅拌条件下加入新制备0.1M氨水10mL，制得磁性铁纳米颗粒(Fe3O4NPs)，通过外加磁场纯化材料，浓缩溶液重新分散于纯水中制得10mM Fe3O4NPs。
8.2制备负载地塞米松(DXMS)和磁性铁纳米颗粒(Fe3O4NPs)脂质体纳米囊泡LP1-(Fe3O4/DXMS)
称取4mg二硬脂酰磷脂酰胆碱(DSPC)、胆固醇、二肉豆蔻酰基磷脂酰乙醇胺(DMPE)(摩尔比为4:1:1)，加入药物地塞米松(DMPE)(药脂摩尔比为1:10)于10mL氯仿溶解。通过缓慢旋转蒸发(65℃水浴，90r/min，30min)除去有机溶剂，从而在容器壁上形成薄膜。加入10mL纯化的1mM的Fe3O4NPs水溶液，将烧瓶放在50℃的恒温水浴锅中使薄膜充分水化，形成粗制脂质体囊泡悬浮液。将粗制脂质体囊泡悬浮液水浴超声，最后用探头超声仪超声处理3min(振幅20，间隔为3s)，得到脂质体囊泡充分分散而形成的分散体系，即精制脂质体囊泡悬浮液。将精制脂质体囊泡悬浮液中未包封的药物和Fe3O4NPs用葡聚糖凝胶柱G-100除去。
8.3制备HI44a修饰的负载Fe3O4/DXMS脂质体纳米囊泡(LP1-(Fe3O4/DXMS)-HI44a)
将1mg HI44a充分溶解于超纯水中，加入0.5mg 1-(3-二甲氨基丙基)-3-乙基碳二亚胺盐酸盐(EDC.HCl)和0.5mgN-羟基硫代琥珀酰亚胺(sulfo-NHS)偶联剂活化羧基。在室温搅拌反应1小时后，超滤离心纯化获得活化的HI44a。将其HI44a溶液溶于纯化的 LP1-(Fe3O4/DXMS)溶液中，实现HI44a在LP1-(Fe3O4/DXMS)上的偶联，得到靶向识别纳米载体LP1-(Fe3O4/DXMS)-HI44a。图9为实施例8中LP1-(Fe3O4/DXMS)-HI44a的表征图。
替换原料，采用以上类似的制备方法本发明人还成功制备靶向MRI示踪剂LP1-(钆特酸葡胺)-HI44a，LP1-(钆双胺)-HI44a和LP1-(钆喷酸)-HI44a等。
实施例9使用单克隆抗体(HI44a)修饰的制备负载地塞米松(IL-10)和磁性铁纳米颗粒(Fe 3O 4NPs)脂质体纳米囊泡LP1-(Fe 3O 4/IL-10)
9.1制备磁性磁性铁纳米颗粒(Fe 3O 4NPs)
按实施8方法制备磁性磁性铁纳米颗粒(Fe 3O 4NPs)
9.2制备负载IL-10和磁性铁纳米颗粒(Fe 3O 4NPs)脂质体纳米囊泡LP1-(Fe 3O 4/IL-10)
称取4mg二硬脂酰磷脂酰胆碱(DSPC)、胆固醇、二肉豆蔻酰基磷脂酰乙醇胺(DMPE)(摩尔比为4:1:1)。通过缓慢旋转蒸发(65℃水浴，90r/min，30min)除去有机溶剂，从而在容器壁上形成薄膜。加入10mL含有Fe 3O 4NPs溶液，将烧瓶放在50℃的恒温水浴锅中使薄膜充分水化，形成粗制脂质体囊泡悬浮液。将粗制脂质体囊泡悬浮液水浴超声，最后用探头超声仪超声处理3min(振幅20，间隔为3s)，得到脂质体囊泡充分分散而形成的分散体系，即精制脂质体囊泡悬浮液，将该溶液浓缩并就加入1mg IL-10室温孵育10小时，得到LP1-(Fe 3O 4/IL-10)。将精制脂质体囊泡中未包封的药物用葡聚糖凝胶柱G-100除去。
8.3制备HI44a修饰的负载Fe 3O 4/IL-10脂质体纳米囊泡(LP1-(Fe 3O 4/IL-10)-HI44a)
将1mg HI44a充分溶解于超纯水中，加入0.5mg 1-(3-二甲氨基丙基)-3-乙基碳二亚胺盐酸盐(EDC.HCl)和0.5mgN-羟基硫代琥珀酰亚胺(sulfo-NHS)偶联剂活化羧基。在室温搅拌反应1小时后，超滤离心纯化获得活化的HI44a。将其HI44a溶液溶于纯化的LP1-(Fe 3O 4/IL-10)溶液中，实现HI44a在LP1-(Fe 3O 4/IL-10)上的偶联，得到靶向识别纳米载体LP1-(Fe 3O 4/IL-10)-HI44a。图10为实施例9中LP1-(Fe3O4/IL-10)-HI44a的红外表征图。
实施例10使用胶原蛋白(Col)修饰的同时负载阿司匹林(Asp),氯吡格雷(Clo)
脂质体囊泡(LP1-(Asp/Clo)-Col)的制备
10.1制备同时负载阿司匹林(Asp)和氯吡格雷(Clo)的脂质体纳米载体(LP1-(Asp/Clo)
称取4mg二硬脂酰磷脂酰胆碱(DSPC)、胆固醇、二肉豆蔻酰基磷脂酰乙醇胺(DMPE)(摩尔比为4:1:1)，加入药物阿司匹林(Asp)和氯吡格雷(Clo)(药物摩尔比例为1:1药物总量与脂质摩尔比为1:10)于10mL氯仿溶解。通过缓慢旋转蒸发(65℃水浴，90r/min，30min)除去有机溶剂，从而在容器壁上形成薄膜。将烧瓶加入10mL纯水，放在50℃的恒温水浴锅中使薄膜充分水化，形成粗制脂质体囊泡悬浮液。将粗制脂质体囊泡悬浮液水浴超声，最后用探头超声仪超声处理3min(振幅20，间隔为3s)，将精制脂质体囊泡悬浮液中未包封的药物用葡聚糖凝胶柱G-100除去。
10.2制备胶原蛋白(Col)修饰的负载脂质体囊泡(LP1-(Asp/Clo)-Col)
将10mg Col充分溶解于超纯水中，加入3mg 1-(3-二甲氨基丙基)-3-乙基碳二亚胺盐酸盐(EDC.HCl)和3mgN-羟基硫代琥珀酰亚胺(sulfo-NHS)偶联剂活化羧基。在室温搅拌反应1小时后，超滤离心纯化获得活化的Col。分别吸取1.0mL Col溶液溶于纯化的LP1-(Asp/Clo)溶液中，实现Col在LP1-(Asp/Clo)上的偶联，得到靶向识别脂质体囊泡LP1-(Asp/Clo)-Col。图11为实施例10中LP1-(Asp/Clo)-Col的红外表征图。
实施例11使用骨桥蛋白(OPN)修饰的负载氟(18F)代脱氧葡糖(F-FDG)脂质体囊泡(LP1-(F-FDG)-OPN)的制备
11.1制备负载F-FDG的脂质体囊泡(LP2-(F-FDG)
称取4mg二硬脂酰磷脂酰胆碱(DSPC)、胆固醇、二肉豆蔻酰基磷脂酰乙醇胺(DMPE)(摩尔比为4:1:1)于10mL氯仿溶解。通过缓慢旋转蒸发(65℃水浴，90r/min，30min)除去有机溶剂，从而在容器壁上形成薄膜。将烧瓶加入10mL的1mg mL-1的F-FDG水溶液(药物总量与脂质摩尔比为1:10)，放在50℃的恒温水浴锅中使薄膜充分水化，形成粗制脂质体囊泡悬浮液。将粗制脂质体囊泡悬浮液水浴超声，最后用探头超声仪超声处理3min(振幅20，间隔为3s)，将精制脂质体囊泡悬浮液中未包封的药物用葡聚糖凝胶柱G-100除去。
11.2制备骨桥蛋白(OPN)修饰的负载F-FDG脂质体囊泡(LP1-(F-FDG)-OPN)
将1mg Col充分溶解于超纯水中，加入0.5mg 1-(3-二甲氨基丙基)-3-乙基碳二亚胺盐酸盐(EDC.HCl)和0.5mgN-羟基硫代琥珀酰亚胺(sulfo-NHS)偶联剂活化羧基。在室温搅拌反应1小时后，超滤离心纯化获得活化的OPN。将其完全溶于纯化的LP1-(F-FDG)溶液中，实现OPN在LP1-(F-FDG)上的偶联，得到靶向识别纳米载体LP1-(F-FDG)-OPN。图12为实施例11中LP1-(F-FDG)-OPN的红外表征图。
试验例1本发明的纳米递送系统的性质考察
在本实施例中，以实施例1中制备的负载治疗剂的纳米递送系统为例来证明本发明的递送系统具有稳定可控的性质，从而适合于易损斑块或与易损斑块相关的疾病的诊断、预防和治疗。
1.药物浓度测定法：
载体药物瑞舒伐他汀，阿托伐他汀、地塞米松、阿司匹林、氯吡格雷、氟(18F)代脱氧葡糖具有很强的紫外吸收特性，因此可以通过采用HPLC-UV法(使用Waters2487，沃特世公司(Waters Corporation)，美国)利用瑞舒伐他汀，阿托伐他汀、地塞米松、阿司匹林、氯吡格雷、氟(18F)代脱氧葡糖的紫外吸收特性测定其含量。用不同浓度的瑞舒伐他汀，阿托伐他汀、地塞米松、阿司匹林、氯吡格雷、氟代脱氧葡萄糖溶液的浓度(X)对HPLC色谱峰的峰面积(Y)建立标准定量方程。
2.水合粒径的测定：
本发明的递送系统LP1-(R)-HA，LP1-(R)-SP，LP1-(R)-HA/Tat，LP2-(At)-HA，LP2-(At)-SEP/IM7，LP2-(At/miRNA-33a)-IM7，LP2-(AuNP/R)-OPN，LP1-(Fe3O4/DXMS)-HI44a，LP1-(Fe3O4/IL-10)-HI44a，LP1-(Asp/Clo)-Col， LP1-(F-FDG)-OPN的水合粒径均由激光粒度仪(BI-Zeta Plus/90Plus，布鲁克海文公司(Brookhaven Instruments Corporation)，美国)测定，具体结果如表1所示。
3.包封率的测定：
取一定质量药物悬浮液，加入过量的甲醇回流提取负载药物，并进一步采用超声提取，使药物加速从载体中释放出来。用HPLC(Waters 2487，沃特世公司(Waters Corporation)，美国)测定所得液体中的药物含量，并通过公式1计算包封率。
Figure PCTCN2019072499-appb-000001
4.载药量的测定：
载药量的测定方法类似于包封率的测定方法，只是计算方法略有不同。取一定质量药物悬浮液，加入过量的甲醇提取负载药物，并进一步采用超声提取，使药物加速从载体中释放出来。用HPLC(Waters 2487，沃特世公司(Waters Corporation)，美国)测定所得液体中的药物含量，并通过以下公式计算载药量。
Figure PCTCN2019072499-appb-000002
用HPLC(Waters 2487，沃特世公司(Waters Corporation)，美国)测定所得液体中的药物含量，并通过公式2计算载药量。
表1各种性质一览表
Figure PCTCN2019072499-appb-000003
Figure PCTCN2019072499-appb-000004
注：以上数据均以平行测定5次的结果的“平均值+标准差”的形式表示。
5.长期稳定性考察
将本发明的纳米递送系统LP1-(R)-HA，LP1-(R)-SP，LP1-(R)-HA/Tat，LP2-(At)-HA，LP2-(At)-SEP/IM7，LP2-(At/miRNA-33a)-IM7，LP2-(AuNP/R)-OPN，LP1-(Fe3O4/DXMS)-HI44a，LP1-(Fe3O4/IL-10)-HI44a，LP1-(Asp/Clo)-Col，LP1-(F-FDG)-OPN在4℃储存，于不同的时间点取样，并通过激光粒度仪(BI-Zeta Plus/90Plus，布鲁克海文公司(Brookhaven Instruments Corporation)，美国)检测其水合粒径的变化，结果见图13所示。图13为长期放置对粒径稳定性的影响。
6.长期稳定性考察将本发明的纳米递送系统LP1-(R)-HA，LP1-(R)-SP，LP1-(R)-HA/Tat，LP2-(At)-HA，LP2-(At)-SEP/IM7，LP2-(At/miRNA-33a)-IM7，LP2-(AuNP/R)-OPN，LP1-(Fe3O4/DXMS)-HI44a，LP1-(Fe3O4/IL-10)-HI44a，LP1-(Asp/Clo)-Col，LP1-(F-FDG)-OPN在在4℃储存，于不同时间点取样，通过超滤离心除去游离药物考察其包封率的变化。结果如图14所示。图14为长期放置对包封率的影响。
7.体外释药性能研究
取2mL本发明的纳米递送系统LP1-(R)-HA，LP1-(R)-SP，LP1-(R)-HA/Tat，LP2-(At)-HA，LP2-(At)-SEP/IM7，LP2-(At/miRNA-33a)-IM7，LP2-(AuNP/R)-OPN，LP1-(Fe3O4/DXMS)-HI44a，LP1-(Fe3O4/IL-10)-HI44a，LP1-(Asp/Clo)-Col，LP1-(F-FDG)-OPN置于透析袋内密封。然后将透析袋置于50mL释放介质(PBS溶液，pH＝7.4)中，于37℃孵育120h。在不同时间点取2mL释放液并补充相同体积的PBS溶液。用HPLC(Waters2487，沃特世公司(Waters Corporation)，美国)检测释放液中的药物含量，并通过公式3计算出药物的累积释放率。
Figure PCTCN2019072499-appb-000005
公式3中各参数意义如下：
CRP：药物累积释放率
Ve：释放液的置换体积，此处Ve为2mL
V0：释放体系中释放液的体积，此处V0为50mL
Ci：第i次置换取样时释放液中药物的浓度，单位μg/mL
M药物：递送系统中的药物的总质量，单位μg
n：置换释放液的次数
Cn：第n次置换释放液后测定的释放体系中的药物浓度。
体外释放是评价纳米粒子递送系统的一项重要指标。图15为本发明的脂质体递送系 统的药物累积释放率变化图。
试验例2靶向机理的研究
在本实施例中，对易损斑块内皮细胞表面上的CD44的密度以及与HA之间的亲和力进行研究，从而为选择易损斑块内的CD44作为本发明所述的靶向易损斑块的递送系统的靶点提供了实验依据。
1)小鼠动脉易损斑块处内皮细胞表面与正常动脉血管壁内皮细胞表面的CD44含量比较：
构建小鼠动脉粥样硬化易损斑块模型。
取SPF级ApoE-/-小鼠(10周龄，体重20±1g)作为实验动物。给予小鼠适应性高脂饮食(脂肪10％(w/w)，胆固醇2％(w/w)，胆酸钠0.5％(w/w)，其余部分为小鼠普通饲料)喂养4周后，用1％的戊巴比妥钠(配制方法为将1mg戊巴比妥钠加入至100ml的生理盐水中)以40mg/kg的剂量腹腔注射麻醉。然后，将小鼠以仰卧位固定于手术板上，用75％(v/v)酒精以颈部为中心进行消毒，纵向剪开颈部皮肤，钝性分离颈前腺体，在气管的左侧可见搏动的左颈总动脉。小心分离颈总动脉至分叉处，将长度为2.5mm、内径为0.3mm的硅胶管套置于左颈总动脉的外周，套管的近心段和远心段均以细丝线缩窄固定。局部紧缩造成近端血流湍流，剪切力增加，造成血管内膜损伤。将颈动脉复位，间断缝合颈前皮肤。所有操作均在10倍体视显微镜下进行。术后待小鼠苏醒后将其放回笼中，维持环境温度在20～25℃，灯光保持开闭各12h。术后第4周开始腹腔注射脂多糖(LPS)(1mg/kg，在0.2ml磷酸盐缓冲盐水中，Sigma,USA)，每周2次，持续10周，诱导慢性炎症。术后8周将小鼠置入50ml注射器(预留充足通气孔)内造成限制性精神应激，6小时/天，每周5天，共持续6周。小鼠动脉粥样硬化易损斑块模型于术后14周造模完毕。图16中的(a)和(b)给出了所述小鼠动脉粥样硬化易损斑块模型的核磁共振成像图，由箭头指向部分可以看出左侧颈动脉斑块已经形成，提示造模成功，右侧劲动脉可作为正常动脉血管壁进行对比。
取模型小鼠的正常动脉血管内皮细胞和动脉易损斑块处内皮细胞，采用免疫组织化学染色和图像分析方法进行CD44含量测定，具体实验方法如下：
取小鼠颈动脉粥样硬化易损斑块标本，经10mL/L甲醛水溶液固定、石蜡包埋、4μm切片、常规脱蜡、水化处理后，采用亲和素-生物素-酶复合物法(SABC)检测CD44含量。将标本浸入30mL/L H2O2水溶液以阻断内源性过氧化物酶的活性，并置入柠檬酸盐缓冲液中行抗原微波修复。然后滴加50g/L牛血清白蛋白(BSA)封闭液，于室温放置20min。然后，滴加鼠抗CD44多克隆抗体(1∶100)，于4℃冰箱放置过夜，再在37℃孵育1h。洗涤后，滴加生物素化的山羊抗鼠IgG，于37℃反应30min。然后用磷酸盐缓冲盐水(PBS)洗涤，并滴加辣根过氧化物酶标记的SABC复合物，于37℃孵育20min；以上每步均用PBS冲洗。最后用DAB显色(显色时在显微镜下控制)，随后用苏木素复染、脱水和封片。采用BI-2000图像分析系统的免疫组织化学分析系统分析切片，其中针对正常动脉血管内皮细胞和动脉易损斑块处内皮细胞组各采集3张切片，随机取5个具有代表性的视野。CD44表达阳性为：细胞膜、细胞质呈棕黄色/棕褐色且背景清晰，并且颜色越深说明CD44表达越强。未出现棕黄颗粒为CD44表达阴性。测量正常动脉血管内皮细胞和动脉易损 斑块处内皮细胞组的阳性细胞平均吸光度(A)值并进行对比。结果如图17所示。
图17示出模型小鼠的正常动脉血管壁内皮细胞和动脉易损斑块处内皮细胞的表面CD44含量测定结果(以半定量积分表示)。如图所示，动脉易损斑块处内皮细胞的表面CD44含量约为正常动脉血管内皮细胞表面CD44含量的2.3倍。
2)小鼠动脉易损斑块处内皮细胞表面与正常动脉血管壁内皮细胞表面的CD44与配体及抗体的亲和力比较：
CD44的天然配体包括：HA、GAG、胶原、层黏连蛋白、纤黏连蛋白、选择蛋白、骨桥蛋白(OPN)以及单克隆抗体HI44a，HI313，A3D8，H90，IM7等。
取模型小鼠的正常动脉血管壁内皮细胞和动脉易损斑块处内皮细胞，加入浓度为10mg/ml的标记有氨基荧光素的配体/抗体，并用杜尔伯科改良伊格尔培养基(DMEM)培养基(含体积分数为10％的小牛血清、100U/ml青霉素、100U/ml链霉素)于37℃、5％CO2培养箱中培养。30分钟后，利用流式细胞仪(CytoFLEX，贝克曼库尔特，美国)测定平均荧光强度(MFI)，并计算两种细胞表面的FL-配体/抗体的结合力积分(以正常动脉血管壁内皮细胞的CD44与配体/抗体的结合力为1)。结果如图18所示。
如图18所示，动脉易损斑块处内皮细胞表面的CD44与HA的结合力积分约为正常动脉血管壁内皮细胞表面的结合力积分的24倍。这表明正常动脉血管壁内皮细胞表面的CD44大多数处于不能与配体HA结合的静止状态，而动脉易损斑块处内皮细胞表面的CD44受到内环境中的诸如炎症因子等因素的影响而激活，与HA的亲和力显著增加。
CD44其他配体，与HA相似，易损斑块内皮细胞表面的CD44与GAG的结合力积分是正常细胞的22倍，易损斑块内皮细胞CD44与胶原的结合力积分是正常细胞的21倍，易损斑块内皮细胞CD44与层黏连蛋白的结合力积分是正常细胞的16倍，易损斑块内皮细胞CD44与纤黏连蛋白的结合力积分是正常细胞的18倍，易损斑块内皮细胞CD44与选择蛋白的结合力积分是正常细胞的19倍，易损斑块内皮细胞CD44与骨桥蛋白的结合力积分是正常细胞的17倍。
CD44单克隆抗体也出现类似结果：易损斑块内皮细胞表面的CD44与H144a的结合力积分是正常细胞的15倍，易损斑块内皮细胞CD44与H1313的结合力积分是正常细胞的21倍，易损斑块内皮细胞CD44与A3D8的结合力积分是正常细胞的17倍，易损斑块内皮细胞CD44与H90的结合力积分是正常细胞的9倍，易损斑块内皮细胞CD44与IM7的结合力积分是正常细胞的8倍。
3)斑块外巨噬细胞和动脉易损斑块内巨噬细胞表面的CD44与配体/抗体的亲和力比较：
取模型小鼠的腹腔内的巨噬细胞和动脉易损斑块内的巨噬细胞，加入浓度为10mg/ml的标记有氨基荧光素的配体/抗体，用DMEM培养基(含体积分数为10％的小牛血清、100U/ml青霉素、100U/ml链霉素)于37℃、5％CO2培养箱中培养。30分钟后，利用流式细胞计(CytoFLEX，贝克曼库尔特，美国)测定平均荧光强度(MFI)，并计算两种细胞表面上的FL-HA的结合力积分(以斑块外巨噬细胞表面的CD44与配体/抗体亲和力为1)。结果如图19所示。
如图19所示，动脉易损斑块内巨噬细胞表面的CD44-HA的结合力约为斑块外巨噬细胞表面的CD44-HA的结合力的40倍。这表明动脉易损斑块内的巨噬细胞表面的CD44 同样受到内环境中的诸如炎症因子等因素的影响而激活，与HA的亲和力显著增加。
CD44其他配体，与HA相似，易损斑块巨噬细胞表面的CD44与GAG的结合力积分是正常细胞的33倍，易损斑块巨噬细胞CD44与胶原的结合力积分是正常细胞的38倍，易损斑块巨噬细胞CD44与层黏连蛋白的结合力积分是正常细胞的37倍，易损斑块巨噬细胞CD44与纤黏连蛋白的结合力积分是正常细胞的35倍，易损斑块巨噬细胞CD44与选择蛋白的结合力积分是正常细胞的33倍，易损斑块巨噬细胞CD44与骨桥蛋白的结合力积分是正常细胞的33倍。
CD44单克隆抗体也出现类似结果：易损斑块巨噬细胞表面的CD44与H144a的结合力积分是正常细胞的17倍，易损斑块巨噬细胞CD44与H1313的结合力积分是正常细胞的20倍，易损斑块巨噬细胞CD44与A3D8的结合力积分是正常细胞的16倍，易损斑块巨噬细胞CD44与H90的结合力积分是正常细胞的9倍，易损斑块巨噬细胞CD44与IM7的结合力积分是正常细胞的10倍。
综合上述实验的结果，可以得出如下结论：与正常细胞(诸如正常动脉血管壁内皮细胞、斑块外巨噬细胞)相比，易损斑块内的细胞(包括内皮细胞、巨噬细胞等，其对于动脉易损斑块的发展具有重要影响)表面上的CD44的密度显著提高，并且与配体的亲和力显著增强，从而导致动脉易损斑块内的CD44与配体的特异性亲和能力远远高于正常细胞，使其非常有利于作为本发明所述的靶向易损斑块的递送系统的优良靶点。
试验例3本发明的LP1-(R)-HA，LP1-(R)-SP，LP1-(R)-HA/Tat瑞舒伐他汀递送系统对动脉易损斑块的影响的体内实验
透明质酸(HA)和选择蛋白(SP)是CD44的配体，能够起到靶向易损斑块的作用，瑞舒伐他汀(R)具有逆转斑块的作用，穿膜肽(Tat)能够增加药物局部穿透和聚集。本实施例的目的是验证本发明所述的LP1-(R)-HA，LP1-(R)-SP，LP1-(R)-HA/Tat载体递送系统对动脉易损斑块的体内治疗作用。
实验方法：
(1)配制游离瑞舒伐他汀的生理盐水溶液，并采用上述实施例1-3中所述的方法制备负载治疗剂的脂质体纳米递送系统。
(2)ApoE-/-小鼠动脉易损斑块模型的建立：
取SPF级ApoE-/-小鼠(42只，5-6周龄，体重20±1g)作为实验动物。给予小鼠适应性高脂饮食(脂肪10％(w/w)，胆固醇2％(w/w)，胆酸钠0.5％(w/w)，其余部分为小鼠普通饲料)喂养4周后，用1％的戊巴比妥钠(配制方法为将1mg戊巴比妥钠加入至100ml的生理盐水中)以40mg/kg的剂量腹腔注射麻醉。然后，将小鼠以仰卧位固定于手术板上，用75％(v/v)酒精以颈部为中心进行消毒，纵向剪开颈部皮肤，钝性分离颈前腺体，在气管的左侧可见搏动的左颈总动脉。小心分离颈总动脉至分叉处，将长度为2.5mm、内径为0.3mm的硅胶管套置于左颈总动脉的外周，套管的近心段和远心段均以细丝线缩窄固定。局部紧缩造成近端血流湍流，剪切力增加，造成的血管内膜损伤。将颈动脉复位，间断缝合颈前皮肤。所有操作均在10倍体视显微镜下进行。术后待小鼠苏醒后将其放回笼中，维持环境温度在20～25℃，灯光保持开闭各12h。术后第4周开始腹腔注射脂多糖(LPS)(1mg/kg，在0.2ml磷酸盐缓冲盐水中，Sigma,USA)，每周2次，持续10周，诱 导慢性炎症。术后8周将小鼠置入50ml注射器(预留充足通气孔)内造成限制性精神应激，6小时/天，每周5天，共持续6周。小鼠动脉粥样硬化易损斑块模型于术后14周造模完毕。
(3)实验动物分组及治疗：
将实验动物随机分为以下各组，每组6只：
易损斑块模型对照组：该组动物不进行任何治疗性处理；
瑞舒伐他汀灌胃组：以10mg瑞舒伐他汀/kg体重的剂量进行灌胃给药处理；
瑞舒伐他汀静脉注射组：以0.66mg瑞舒伐他汀/kg体重的剂量进行静脉注射给药处理；
LP1-(R)-HA组：以0.66mg瑞舒伐他汀/kg体重的剂量进行静脉注射给药处理；
LP1-(R)-SP组：以0.66mg瑞舒伐他汀/kg体重的剂量进行静脉注射给药处理；
LP1-(R)-HA/Tat组：以0.66mg瑞舒伐他汀/kg体重的剂量进行静脉注射给药处理。
除易损斑块模型对照组外，治疗组的治疗每隔一天进行1次，共治疗5次。对于各组动物，于治疗前后进行颈动脉MRI扫描以检测斑块和管腔面积，并计算斑块进展百分比。
斑块进展百分比＝(治疗后斑块面积-治疗前斑块面积)/管腔面积。
实验结果：
图20展示了本发明所述的LP1-(R)-HA，LP1-(R)-SP，LP1-(R)-HA/Tat载体递送系统对动脉易损斑块的体内治疗效果。如图所示，高脂饮食喂养的过程中(10天)，对照组(不给于任何治疗处理)的动脉粥样硬化进展了36.23％；采用瑞舒伐他汀灌胃治疗，能够延缓斑块的进展，但也进展了33.9％；瑞舒伐他汀静脉注射同样延缓斑块进展，但也进展了32.46％；而靶向纳米载药治疗则明显遏制了斑块的进展，甚至出现了斑块体积的逆转和消退，LP1-(R)-HA组使斑块消除10.87％，LP1-(R)-SP使斑块消除8.74％，LP1-(R)-HA/Tat组使斑块消除13.2％。
综上所述，对于小鼠体内动脉易损斑块而言，无论是灌胃给药还是静脉注射给药，游离的瑞舒伐他汀都呈现出了一定的治疗效果，但是其无法阻止易损斑块的继续生长。然而，当将瑞舒伐他汀配制在本发明所述的纳米递送系统中时，其对于易损斑块的治疗效果发生了显著的提升，并起到了逆转斑块生长(缩小斑块)的治疗效果，带有功能修饰的纳米系统效果更佳。
试验例4本发明的LP2-(At)-HA，LP2-(At)-SEP/IM7，LP2-(At/miRNA-33a)-IM7递送系统对动脉易损斑块的影响的体内实验
透明质酸(HA)和IM7是CD44的配体，能够起到靶向易损斑块的作用，阿托伐他汀(At)具有逆转斑块的作用，自身肽(SEP)能够增加药物局部穿透和聚集，miRNA-33a能够增加胆固醇流出。本实施例的目的是验证本发明所述的LP2-(At)-HA，LP2-(At)-SEP/IM7，LP2-(At/miRNA-33a)-IM7载体递送系统对动脉易损斑块的体内治疗作用。
实验方法：
(1)配制游离阿托伐他汀的生理盐水溶液，并采用上述实施例4-6中所述的方法制 备负载治疗剂的中空二氧化硅纳米递送系统。
(2)ApoE-/-小鼠动脉易损斑块模型的建立方法同试验例4。
(3)实验动物分组及治疗：
将实验动物随机分为以下各组，每组6只：
易损斑块模型对照组：该组动物不进行任何治疗性处理；
阿托伐他汀灌胃组：以20mg阿托伐他汀/kg体重的剂量进行灌胃给药处理；
阿托伐他汀静脉注射组：以1.2mg阿托伐他汀/kg体重的剂量进行静脉注射给药处理；
不含PEG的LP2-(At)-HA组：以1.2mg阿托伐他汀/kg体重的剂量进行静脉注射给药处理；
LP2-(At)-HA组：以1.2mg阿托伐他汀/kg体重的剂量进行静脉注射给药处理；
LP2-(At)-IM7组：以1.2mg阿托伐他汀/kg体重的剂量进行静脉注射给药处理；
LP2-(At)-SEP/IM7组：以1.2mg阿托伐他汀/kg体重的剂量进行静脉注射给药处理；
LP2-(At/miRNA-33a)-IM7组：以1.2mg阿托伐他汀/kg体重的剂量进行静脉注射给药处理。
除易损斑块模型对照组外，治疗组的治疗每隔一天进行1次，共治疗5次。对于各组动物，于治疗前后进行颈动脉MRI扫描以检测斑块和管腔面积，并计算斑块进展百分比。
斑块进展百分比＝(治疗后斑块面积-治疗前斑块面积)/管腔面积。
实验结果：
图21展示了本发明所述的LP2-(At)-HA，LP2-(At)-SEP/IM7，LP2-(At/miRNA-33a)-IM7系统对动脉易损斑块的体内治疗效果。如图所示，高脂饮食喂养的过程中(10天)，对照组(不给于任何治疗处理)的动脉粥样硬化进展了34.87％；采用阿托伐他汀灌胃治疗，能够延缓斑块的进展，但也进展了33.21％；阿托伐他汀静脉注射同样延缓斑块进展，但也进展了32.98％；而靶向纳米载药治疗则明显遏制了斑块的进展，甚至出现了斑块体积的逆转和消退，不含PEG的LP2-(At)-HA组使斑块消除6.9％，LP2-(At)-HA组使斑块消除12.65％，LP2-(At)-IM7组使斑块消除5.1％，LP2-(At)-SEP/IM7组使斑块消除12.43％，LP2-(At/miRNA-33a)-IM7组使斑块消除14.22％。
综上所述，对于小鼠体内动脉易损斑块而言，无论是灌胃给药还是静脉注射给药，游离的阿托伐他汀都呈现出了一定的治疗效果，但是其无法阻止易损斑块的继续生长。然而，当将阿托伐他汀配制在本发明所述的脂质体纳米递送系统中时，其对于易损斑块的治疗效果发生了显著的提升，并起到了逆转斑块生长(缩小斑块)的治疗效果。采用PEG或SEP功能修饰的纳米载体效果更佳，同时负载他汀和核酸的纳米载体药效显著。
试验例5本发明的LP2-(AuNP/R)-OPN递送系统对动脉易损斑块的影响的体内实验(CT示踪及治疗双功能)
骨桥蛋白(OPN)是CD44的配体，能够起到靶向易损斑块的作用，瑞舒伐他汀(R)具有逆转斑块的作用，纳米金(AuNP)是CT示踪剂。本实施例的目的是验证本发明所 述的负载CT示踪剂和瑞舒伐他汀的纳米递送系统对动脉易损斑块的体内示踪及治疗效果。
(1)配制游离瑞舒伐他汀的生理盐水溶液，并采用上述实施例7中所述的方法制备负载CT示踪剂和治疗剂的脂质体纳米递送系统。
(2)ApoE-/-小鼠动脉易损斑块模型的建立方法同试验例4。
(3)实验动物易损斑块示踪：
将实验动物随机分为以下各组，每组6只：
游离纳米金颗粒组：纳米金的给药剂量为0.1mg/kg体重；
LP2-(AuNP/R)-OPN组：纳米金的给药剂量为0.1mg/kg体重；
LP2-(碘普罗胺)-OPN组：碘普罗胺的给药剂量为0.1mg/kg体重；
LP2-(碘克沙醇)-OPN组；碘克沙醇的给药剂量为0.1mg/kg体重；
LP2-(碘氟醇)-OPN组：碘氟醇的给药剂量为0.1mg/kg体重。
各实验组分别经尾静脉注入相应的示踪剂，并于给药前以及给药后2h进行CT成像，观察各组动物的动脉粥样硬化易损斑块的识别情况。
(4)实验动物分组及治疗：
将实验动物随机分为以下各组，每组6只：
易损斑块模型对照组：该组动物不进行任何治疗性处理；
瑞舒伐他汀灌胃组：以10mg瑞舒伐他汀/kg体重的剂量进行灌胃给药处理；
瑞舒伐他汀静脉注射组：以0.67mg瑞舒伐他汀/kg体重的剂量进行静脉注射给药处理；
LP2-(AuNP/R)-OPN组：以0.67mg瑞舒伐他汀/kg体重的剂量进行静脉注射给药处理；
除易损斑块模型对照组外，治疗组的治疗每隔一天进行1次，共治疗5次。对于各组动物，于治疗前后进行颈动脉MRI扫描以检测斑块和管腔面积，并计算斑块进展百分比。
斑块进展百分比＝(治疗后斑块面积-治疗前斑块面积)/管腔面积。
实验结果：
图22展示了本发明所述的负载示踪剂的脂质体递送系统对动脉易损斑块的体内示踪效果。如图所示，游离的纳米金颗粒对于小鼠体内动脉易损斑块而言呈现出了一定的示踪效果。与游离的纳米金颗粒相比，当将纳米金，碘普罗胺，碘克沙醇，碘氟醇配制在靶向的脂质体递送系统中时，其对于易损斑块的示踪效果有了非常显著的提高。综上所述，与游离纳米金颗粒相比，使用本发明所述的表面修饰有靶向配体的脂质体递送系统给药可显著提高纳米金对动脉易损斑块的识别作用，产生更好的示踪效果。
图23展示了本发明所述的LP2-(AuNP/R)-OPN系统对动脉易损斑块的体内治疗效果。如图所示，高脂饮食喂养的过程中(10天)，对照组(不给于任何治疗处理)的动脉粥样硬化进展了31.23％；采用瑞舒伐他汀灌胃治疗，能够延缓斑块的进展，但也进展了30.9％；瑞舒伐他汀静脉注射同样延缓斑块进展，但也进展了25.34％；而靶向纳米载药治疗则明显遏制了斑块的进展，甚至出现了斑块体积的逆转和消退，LP2-(AuNP/R)-OPN使斑块消退了8.32％。
综上所述，对于小鼠体内动脉易损斑块而言，无论是灌胃给药还是静脉注射给药，游离的瑞舒伐他汀都呈现出了一定的治疗效果，但是其无法阻止易损斑块的继续生长。然而，当将瑞舒伐他汀和纳米金配制在本发明所述的纳米递送系统中时，其对于易损斑块的诊断和治疗效果发生了显著的提升，并起到了高危患者预警，以及逆转斑块生长(缩小斑块)的治疗效果。
试验例6本发明的LP1-(Fe3O4/DXMS)-HI44a，LP1-(Fe3O4/IL-10)-HI44a递送系统对动脉易损斑块的体内示踪实验(MRI示踪)及抗炎治疗
单克隆抗体(HI44a)是CD44的抗体，能够起到靶向易损斑块的作用，地塞米松(DXMS)具有抗炎，抑制斑块进展的作用，Fe3O4是MRI示踪剂。本实施例的目的是验证本发明所述的负载MRI示踪剂和地塞米松的纳米递送系统对动脉易损斑块的体内示踪及治疗效果。另外，钆特酸葡胺，钆双胺，钆喷酸也可以制备成纳米制剂，显示靶向MRI示踪效果。
(1)采用上述实施例8-9中所述的方法制备负载MRI示踪剂和治疗剂的脂质体纳米递送系统。
(2)ApoE-/-小鼠动脉易损斑块模型的建立方法同试验例4。
(3)实验动物易损斑块示踪：
将实验动物随机分为以下各组，每组6只：
游离Fe3O4组：Fe3O4的给药剂量为0.1mg/kg体重
LP1-(Fe3O4/DXMS)-HI44a组：Fe3O4的给药剂量为0.1mg/kg体重；
LP1-(Fe3O4/IL-10)-HI44a组：Fe3O4的给药剂量为0.1mg/kg体重；
LP1-(钆特酸葡胺)-HI44a组：钆特酸葡胺的给药剂量为0.1mg/kg体重；
LP1-(钆双胺)-HI44a组：钆双胺的给药剂量为0.1mg/kg体重；
LP1-(钆喷酸)-HI44a组：钆喷酸的给药剂量为0.1mg/kg体重。
各实验组分别经尾静脉注入相应的示踪剂，并于给药前以及给药后2h进行MRI成像，观察各组动物的动脉粥样硬化易损斑块的识别情况。
(4)实验动物分组及治疗：
将实验动物随机分为以下各组，每组6只：
易损斑块模型对照组：该组动物不进行任何治疗性处理；
LP1-(Fe3O4/DXMS)-HI44a组：以0.1mg地塞米松/kg体重的剂量进行静脉注射给药处理；
LP1-(Fe3O4/IL-10)-HI44a组：以0.1微摩IL-10/kg体重的剂量进行静脉注射给药处理。
除易损斑块模型对照组外，治疗组的治疗每隔一天进行1次，共治疗5次。对于各组动物，于治疗前后进行颈动脉MRI扫描以检测斑块和管腔面积，并计算斑块进展百分比。
斑块进展百分比＝(治疗后斑块面积-治疗前斑块面积)/管腔面积。
实验结果：
图24展示了本发明所述的负载示踪剂的脂质体递送系统对动脉易损斑块的体内示踪 效果。如图所示，游离的Fe3O4颗粒对于小鼠体内动脉易损斑块而言呈现出了一定的示踪效果。与游离的Fe3O4颗粒相比，当将Fe3O4配制在靶向的脂质体递送系统中时，其对于易损斑块的示踪效果有了非常显著的提高，采用其他MRI纳米造影剂，易损斑块的示踪效果也很不错。综上所述，与游离MRI示踪剂相比，使用本发明所述的表面修饰有靶向配体的脂质体递送系统给药可显著提高MRI示踪剂对动脉易损斑块的识别作用，产生更好的示踪效果。
图25展示了本发明所述的LP1-(Fe3O4/DXMS)-HI44a系统和LP1-(Fe3O4/IL-10)-HI44a系统对动脉易损斑块的体内治疗效果。如图所示，高脂饮食喂养的过程中(10天)，对照组(不给于任何治疗处理)的动脉粥样硬化进展了23.65％；而靶向纳米载药治疗则明显遏制了斑块的进展，甚至出现了斑块体积的逆转和消退，LP1-(Fe3O4/DXMS)-HI44a使斑块消退了9.54％，LP1-(Fe3O4/IL-10)-HI44a使斑块消退了5.43％。
综上所述，对于小鼠体内动脉易损斑块而言，当将地塞米松或IL-10等抗炎物质配制在本发明所述的纳米递送系统中时，其对于易损斑块的诊断和治疗效果发生了显著的提升，并起到了高危患者预警，以及逆转斑块生长(缩小斑块)的治疗效果。同时负载Fe3O4可以起到MRI成像，实时监控病情的效果。
试验例7本发明的LP1-(Asp/Clo)-Col递送系统对动脉易损斑块的影响的体内实验
阿司匹林(Asp)和氯吡格雷(Clo)是抗血小板药物，能够起到减少血小板聚集的作用，可以减少心血管事件的死亡率。本实施例的目的是验证本发明所述的LP1-(Asp/Clo)-Col载体递送系统对动脉易损斑块的体内治疗作用。
实验方法：
(1)配制游离阿司匹林和氯吡格雷的生理盐水溶液，并采用上述实施例10中所述的方法制备负载治疗剂的脂质体纳米递送系统。
(2)ApoE-/-小鼠动脉易损斑块破裂模型的建立：给予高脂饮食喂养30周，使ApoE-/-小鼠全身动脉形成动脉粥样硬化斑块，给予蛇毒诱导易损斑块破裂，形成急性冠脉综合征。
(3)实验动物分组及治疗：
将实验动物随机分为以下各组，每组10只：
斑块破裂模型对照组：该组动物不进行任何治疗性处理；
阿司匹林和氯吡格雷灌胃组：以100mg阿司匹林/kg体重和75mg氯吡格雷/kg体重的剂量进行灌胃给药处理；
LP1-(Asp/Clo)-Col组：以10mg阿司匹林/kg体重和7.5mg氯吡格雷/kg体重的剂量进行静脉注射给药处理；
除易损斑块模型对照组外，治疗组的治疗每隔一天进行1次，共治疗5次。对于各组动物，观察1月小鼠的死亡率，并断尾检测小鼠出血时间(BT)。
实验结果：
图26展示了本发明所述的LP1-(Asp/Clo)-Col系统对动脉易损斑块的体内治疗效果。如图所示，对照组(不给于任何治疗处理)的小鼠死亡率50％；采用阿司匹林和氯吡格雷灌 胃治疗，能够使死亡率下降至30％；LP1-(Asp/Clo)-Col治疗能够使死亡率下降至10％。从出血时间来看，LP1-(Asp/Clo)-Col组未显著延长，而口服阿司匹林和氯吡格雷的小鼠出血时间显著延长。
综上所述，对于易损斑块破裂的动物而言，口服双抗血小板治疗可以降低死亡率，但是延长出血时间，增加出血风险。而本发明所述的将抗血小板药物负载至纳米递送系统，起到了比口服药物更好的疗效，且不增加出血风险。
试验例8本发明的LP1-(F-FDG)-OPN递送系统对动脉易损斑块的影响的体内实验
骨桥蛋白(OPN)是CD44的配体，能够起到靶向易损斑块的作用，瑞舒伐他汀(R)具有逆转斑块的作用，氟18脱氧葡萄糖(F-FDG)是核素示踪剂。本实施例的目的是验证本发明所述的负载核素示踪剂的脂质体纳米递送系统对动脉易损斑块的体内示踪及治疗效果。
(1)配制游离瑞舒伐他汀的生理盐水溶液，并采用上述实施例11中所述的方法制备负载核素示踪剂的脂质体纳米递送系统。
(2)ApoE-/-小鼠动脉易损斑块模型的建立方法同试验例4。
(3)实验动物易损斑块示踪：
将实验动物随机分为以下各组，每组6只：
游离F-FDG组：F-FDG的给药剂量为2mSv/kg体重；
LP1-(F-FDG)-OPN组：纳米金的给药剂量为2mSv/kg体重；
LP1-(99mTc)-OPN组：碘普罗胺的给药剂量为2mSv/kg体重；
LP1-(I-131)-OPN组；碘克沙醇的给药剂量为2mSv/kg体重。
各实验组分别经尾静脉注入相应的示踪剂，并于给药前以及给药后2h进行核素成像，观察各组动物的动脉粥样硬化易损斑块的识别情况。
实验结果：
图27展示了本发明所述的负载核素示踪剂的脂质体递送系统对动脉易损斑块的体内示踪效果。如图所示，游离的F-FDG对于小鼠体内动脉易损斑块而言未呈现示踪效果。当将F-FDG，锝99(99mTc)，碘131(I-131)配制在靶向的脂质体递送系统中时，其对于易损斑块的示踪效果有了非常显著的提高。综上所述，与游离F-FDG相比，使用本发明所述的表面修饰有靶向配体的脂质体递送系统给药可显著提高核素示踪剂对动脉易损斑块的识别作用，产生良好的示踪效果。
已经通过上述实施例对本发明的各个方面进行了例示。显然，上述实施例仅仅是为清楚地说明所作的举例，而并非对实施方式的限定。对于所属领域的普通技术人员来说，在上述说明的基础上还可以做出其它不同形式的变化或变动。这里无需也无法对所有的实施方式予以穷举。而由此所引伸出的显而易见的变化或变动仍处于本发明创造的保护范围之中。

Claims (20)

  1. 一种用于靶向活化的CD44分子的脂质体纳米载体递送系统，其特征在于，所述纳米载体的表面部分地被靶向配体修饰，所述靶向配体是能与活化的CD44分子特异性结合的配体；
    任选地，纳米载体表面可以进行其他修饰，所属修饰优选为在载体表面修饰PEG、穿膜肽、自身肽SEP中的一种或多种，或者双重配体同时修饰。
  2. 一种用于靶向易损斑块的脂质体纳米载体递送系统，其特征在于，所述纳米载体的表面部分地被靶向配体修饰，所述靶向配体是能与易损斑块处的细胞表面上的CD44分子特异性结合的配体；
    任选地，纳米载体表面可以进行其他修饰，所属修饰优选为在载体表面修饰PEG、穿膜肽、自身肽SEP中的一种或多种，或者双重配体同时修饰。
  3. 根据权利要求1或2所述的纳米载体递送系统，其特征在于，所述脂质体载体选自小单室脂质体、大单室脂质体、多室脂质体。
  4. 根据权利要求1至3中任一项所述的纳米载体递送系统，其特征在于，所述靶向配体选自GAG、胶原、层黏连蛋白、纤黏连蛋白、选择蛋白、骨桥蛋白(OPN)以及单克隆抗体HI44a，HI313，A3D8，H90，IM7，或透明质酸或能够与易损斑块处的细胞表面上的CD44分子特异性结合的透明质酸的衍生物；
    优选地，所述靶向配体选自胶原，透明质酸，选择蛋白，骨桥蛋白或单克隆抗体HI44a，IM7。
  5. 根据权利要求1至4中任一项所述的纳米载体递送系统，其特征在于，所述纳米载体负载有用于诊断、预防和/或治疗与出现CD44分子活化状况相关的疾病的物质。
  6. 根据权利要求1至5所述的纳米载体递送系统，其特征在于，所述纳米载体负载有用于诊断、预防和/或治疗易损斑块或与易损斑块相关的疾病的物质；
    优选地，所述所述物质是用于诊断易损斑块或与易损斑块相关的疾病的物质；
    更优选地，所述用于诊断易损斑块或与易损斑块相关的疾病的物质是示踪剂；
    进一步优选地，所述示踪剂选自CT示踪剂、MRI示踪剂和核素示踪剂；
    更进一步优选地：
    所述CT示踪剂选自碘纳米造影剂、金纳米造影剂、氧化钽纳米造影剂、铋纳米造影剂、镧系纳米造影剂，或其他类似结构的示踪剂；更优选为碘化造影剂或纳米金，或其他类似结构的示踪剂；进一步优选为碘海醇、碘卡酸、碘佛醇、碘克沙醇、碘普罗胺、碘比醇、碘美普尔、碘帕醇、碘昔兰、醋碘苯酸、胆影酸、碘苯扎酸、碘甘卡酸、泛影酸、碘他拉酸钠、碘苯酯、碘番酸、碘阿芬酸、醋碘苯酸钠、碘多啥、丙碘酮、碘奥酮、碘曲仑、 碘吡多、胆影酸葡甲胺、碘他拉酸、泛影葡胺、甲泛影酸、甲泛葡铵、碘化油或乙碘油，或其他类似结构的示踪剂，优选为纳米金；
    所述MRI示踪剂选自纵向弛豫造影剂和横向弛豫造影剂；更优选为顺磁性造影剂、铁磁性造影剂和超磁性造影剂；进一步优选为Gd-DTPA及其线型、环型多胺多羧类螯合物和锰的卟啉螯合物，大分子钆螯合物、生物大分子修饰的钆螯合物、叶酸修饰的钆螯合物、树状大分子显影剂、脂质体修饰的显影剂和含钆富勒烯，或其他类似结构的示踪剂；再优选为钆喷酸葡胺、钆特酸葡胺、钆贝葡胺、钆双胺、枸橼酸铁铵泡腾颗粒、顺磁性氧化铁(Fe 3O 4NPs)，或其他类似结构的示踪剂，优选为Fe 3O 4NPs；和/或
    所述核素示踪剂选自有碳14(14C)、碳13(13C)、磷32(32P)、硫35(35S)、碘131(131I)、氢3(3H)、锝99(99Tc)、氟18(18F)标记的氟代脱氧葡萄糖；优选为氟18标记的氟代脱氧葡萄糖。
  7. 根据权利要求6所述的纳米载体递送系统，其特征在于，所述物质是用于诊断、预防和/或治疗易损斑块或与易损斑块相关的疾病的药物、多肽、核酸和细胞因子中的一种或多种。
  8. 根据权利要求5至7中任一项所述的纳米载体递送系统，其特征在于，所述物质是CD44活化剂；
    优选地，所述CD44活化剂是CD44抗体mAb或IL5、IL12、IL18、TNF-α、LPS。
  9. 根据权利要求5至8中任一项所述的纳米载体递送系统，其特征在于，所述物质是小分子透明质酸或能够与易损斑块处的细胞表面上的CD44分子特异性结合的透明质酸的衍生物；
    优选地，所述小分子透明质酸或能够与易损斑块处的细胞表面上的CD44分子特异性结合的透明质酸的衍生物的分子量范围1-500KDa，优选为1-20KDa，更优选为2-10KDa。
  10. 根据权利要求6至9中任一项所述的纳米载体递送系统，其特征在于，所述纳米载体同时负载有用于诊断、预防和/或治疗易损斑块或与易损斑块相关的疾病的物质和CD44活化剂；
    优选地，所述纳米载体同时负载有用于预防和/或治疗易损斑块或与易损斑块相关的疾病的物质和透明质酸或能够与易损斑块处的细胞表面上的CD44分子特异性结合的透明质酸的衍生物；
    更优选地，所述纳米载体同时负载有用于诊断易损斑块或与易损斑块相关的疾病的物质、用于预防和/或治疗易损斑块或与易损斑块相关的疾病的物质、任选的CD44活化剂和任选的透明质酸或能够与易损斑块处的细胞表面上的CD44分子特异性结合的透明质酸的衍生物。
  11. 根据权利要求6所述的纳米载体递送系统，其特征在于，所述物质是用于预防和/或治疗易损斑块或与易损斑块相关的疾病的物质；
    优选地，所述用于预防和/或治疗易损斑块或与易损斑块相关的疾病的物质选自他汀类药物、贝特类药物、抗血小板药物、PCSK9抑制剂、抗凝药物、血管紧张素转换酶抑制剂(ACEI)、钙离子拮抗剂、MMPs抑制剂、β受体阻滞剂，糖皮质激素或其他的抗炎物质如IL-1抗体canakinumab，以及它们的药学上可接受的盐中的一种或多种，包括这些种类药物或物质的活性制剂，以及内源性的抗炎细胞因子比如白细胞介素10(IL-10)；
    更优选地，所述用于预防和/或治疗易损斑块或与易损斑块相关的疾病的物质选自洛伐他汀、阿托伐他汀、瑞舒伐他汀、辛伐他汀、氟伐他汀、匹伐他汀、普伐他汀，苯扎贝特、环丙贝特、氯贝特、吉非贝齐、非诺贝特、普罗布考，抗PCSK9抗体如evolocumab、alirocumab、bococizumab、RG7652、LY3015014和LGT-209，或adnectin如BMS-962476，反义RNAi寡核苷酸如ALN-PCSsc，核酸如microRNA-33a、microRNA-27a/b、microRNA-106b、microRNA-302、microRNA-758、microRNA-10b、microRNA-19b、microRNA-26、microRNA-93、microRNA-128-2、microRNA-144、microRNA-145反义链以及它们的核酸类似物如锁核酸，阿司匹林、阿西美辛、曲克芦丁、双嘧达莫、西洛他唑、盐酸噻氯匹定、奥扎格雷钠、氯吡格雷、普拉格雷、西洛他唑、贝列前素钠、替格瑞洛、坎格瑞洛、替罗非班、依替巴肽、阿昔单抗、普通肝素、克赛、速碧林、黄达肝葵钠、华法林、达比加群、利伐沙班、阿哌沙班、依度沙班、比伐卢定、依诺肝素、替他肝素、阿地肝素、双香豆素、硝酸香豆素、枸杞酸钠、水蛭素、阿加曲班，贝那普利、卡托普利、依那普利、培多普利、福辛普利、赖诺普利、莫昔普利、西拉普利、培哚普利、喹那普利、雷米普利、群多普利、坎地沙坦，依普罗沙坦、厄贝沙坦、氯沙坦、替米沙坦、缬沙坦、奥美沙坦、他索沙坦、硝苯地平、尼卡地平、尼群地平、氨氯地平、尼莫地平、尼索地平、尼伐地平、伊拉地平、非洛地平、拉西地平、地尔硫卓、维拉帕米、氯己定、米诺环素、MMI-166、美托洛尔、阿替洛尔、比索洛尔、普萘洛尔、卡维地络、巴马司他、马立马司他、普啉司他、BMS-279251、BAY 12-9566、TAA211、AAJ996A、nacetrapib、evacetrapib、Torcetrapib和Dalcetrapib，泼尼松、甲泼尼松、倍他米松、丙酸倍氯米松、得宝松、泼尼松龙、氢化可的松、地塞米松或其他的抗炎物质如IL-1抗体canakinumab)，以及它们的药效片段或药学上可接受的盐中的一种或多种，以及它们的药学上可接受的盐中的一种或多种，包括这些种类药物的活性结构片段，以及内源性的抗炎细胞因子比如白细胞介素10(IL-10)。
  12. 一种用于制备权利要求1至11中任一项所述的用于靶向易损斑块的纳米递送系统的方法，其特征在于，所述方法包括以下步骤：
    (1)将适量的磷脂分子溶解于合适的有机溶剂中，通过薄膜水化法制备脂质体纳米载体，对于极性较差的药物分子，需要在这一步和磷脂分子共同成膜；
    (2)任选地向步骤(1)所得纳米载体递送系统中加入任选含有水溶性的用于诊断、预防和/或治疗易损斑块或与易损斑块相关的疾病的物质的水性介质，形成粗制悬浮液；
    (3)将靶向配体溶解于合适的缓冲溶液溶剂中，将步骤(2)所得的载体分子加入靶向配体溶液中进行反应，得到所述纳米载体递送系统；
    (4)任选地通过透析法除去步骤(3)中得到的所述粗制悬浮液中所含有的未负载的用于诊断、预防和/或治疗易损斑块或与易损斑块相关的疾病的物质，得到负载的纳米递 送系统。
  13. 一种药物，其特征在于，所述药物包含权利要求1至11中任一项所述的纳米载体递送系统以及药学上可接受的载体。
  14. 一种诊断制剂，其特征在于，所述诊断制剂包含权利要求1至11中任一项所述的纳米载体递送系统。
  15. 权利要求1至11中任一项所述的纳米载体递送系统、权利要求13所述的药物、或权利要求14所述的诊断制剂在制备用于预防和/或治疗与出现CD44分子活化状况相关的疾病的药物中的用途。
  16. 权利要求1至11中任一项所述的纳米载体递送系统、权利要求13所述的药物、或权利要求14所述的诊断制剂在制备用于预防和/或治疗与易损斑块或与易损斑块相关的疾病的药物和/或诊断制剂中的用途。
  17. 根据权利要求16所述的用途，其特征在于，所述易损斑块选自破裂斑块、侵蚀性斑块和部分钙化结节性病变中的一种或多种；
    优选地，所述与易损斑块相关的疾病选自动脉粥样硬化症、冠状动脉粥样硬化性心脏病(包括急性冠脉综合征、无症状心肌缺血-隐匿性冠心病、心绞痛、心肌梗死、缺血性心脏病、猝死、支架内再狭窄)、脑动脉粥样硬化症(包括脑卒中)、外周血管动脉粥样硬化症(包括闭塞性周围动脉粥样硬化、视网膜动脉粥样硬化症、颈动脉粥样硬化症、肾动脉粥样硬化症、下肢动脉粥样硬化症、上肢动脉粥样硬化症、动脉粥样硬化性阳痿)、主动脉夹层、血管瘤、血栓栓塞、心力衰竭和心源性休克中的一种或多种。
  18. 一种用于预防和/或治疗与出现CD44分子活化状况相关的疾病的方法，其特征在于，所述方法包括：对有需要的受试者给予权利要求1至11中任一项所述的纳米载体递送系统、权利要求13所述的药物、或权利要求14所述的诊断制剂。
  19. 一种用于预防、诊断和/或治疗易损斑块或与易损斑块相关的疾病的方法，其特征在于，所述方法包括：对有需要的受试者给予权利要求1至11中任一项所述的纳米载体递送系统、权利要求13所述的药物、或权利要求14所述的诊断制剂；
    优选地，所述易损斑块选自破裂斑块、侵蚀性斑块和部分钙化结节性病变中的一种或多种；
    更优选地，所述与易损斑块相关的疾病选自动脉粥样硬化症、冠状动脉粥样硬化性心脏病(包括急性冠脉综合征、无症状心肌缺血-隐匿性冠心病、心绞痛、心肌梗死、缺血性心脏病、猝死、支架内再狭窄)、脑动脉粥样硬化症(包括脑卒中)、外周血管动脉粥样硬化症(包括闭塞性周围动脉粥样硬化、视网膜动脉粥样硬化症、颈动脉粥样硬化症、肾动脉粥样硬化症、下肢动脉粥样硬化症、上肢动脉粥样硬化症、动脉粥样硬化性阳痿)、 主动脉夹层、血管瘤、血栓栓塞、心力衰竭和心源性休克中的一种或多种。
  20. 一种用于诊断与出现CD44分子活化状况相关的疾病的方法，其特征在于，所述方法包括包括：对有需要的受试者给予权利要求1至11中任一项所述的纳米载体递送系统、权利要求13所述的药物、或权利要求14所述的诊断制剂。
PCT/CN2019/072499 2018-01-22 2019-01-21 用于靶向活化cd44分子的脂质体纳米载体递送系统、其制备方法和用途 WO2019141271A1 (zh)

Priority Applications (9)

Application Number Priority Date Filing Date Title
AU2019208796A AU2019208796B2 (en) 2018-01-22 2019-01-21 Liposomal nanocarrier delivery system for targeting active CD44 molecule, preparation method therefor, and uses thereof
EP19741349.5A EP3744317A4 (en) 2018-01-22 2019-01-21 LIPOSOMAL NANOCARRIER DELIVERY SYSTEM FOR TARGETING CD44 ACTIVE MOLECULE, THE METHOD FOR ITS MANUFACTURING AND ITS USES
JP2020538853A JP7436367B2 (ja) 2018-01-22 2019-01-21 活性ｃｄ４４分子を標的とするためのリポソームナノ担体送達系、その調製方法、及びその使用
CN201980001843.4A CN110545798B (zh) 2018-01-22 2019-01-21 用于靶向活化cd44分子的脂质体纳米载体递送系统、其制备方法和用途
KR1020207021204A KR20200111185A (ko) 2018-01-22 2019-01-21 활성 cd44 분자를 표적하기 위한 리포솜 나노캐리어 전달 시스템, 이의 제조 방법, 및 이의 용도
CA3087606A CA3087606A1 (en) 2018-01-22 2019-01-21 Liposomal nanocarrier delivery system for targeting active cd44 molecule, preparation method therefor, and uses thereof
US16/961,349 US20200397926A1 (en) 2018-01-22 2019-01-21 Liposomal nanocarrier delivery system for targeting active cd44 molecule,preparation method therefor, and uses thereof
JP2023196823A JP2024014986A (ja) 2018-01-22 2023-11-20 活性ｃｄ４４分子を標的とするためのリポソームナノ担体送達系、その調製方法、及びその使用
US18/530,122 US20240148913A1 (en) 2018-01-22 2023-12-05 Liposomal nanocarrier delivery system for targeting active cd44 molecule,preparation method therefor, and uses thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201810060265.9 2018-01-22
CN201810060265 2018-01-22

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US16/961,349 A-371-Of-International US20200397926A1 (en) 2018-01-22 2019-01-21 Liposomal nanocarrier delivery system for targeting active cd44 molecule,preparation method therefor, and uses thereof
US18/530,122 Division US20240148913A1 (en) 2018-01-22 2023-12-05 Liposomal nanocarrier delivery system for targeting active cd44 molecule,preparation method therefor, and uses thereof

Publications (1)

Publication Number Publication Date
WO2019141271A1 true WO2019141271A1 (zh) 2019-07-25

Family

ID=67301670

Family Applications (9)

Application Number Title Priority Date Filing Date
PCT/CN2019/072559 WO2019141275A1 (zh) 2018-01-22 2019-01-21 用于靶向活化cd44分子的硅质体纳米载体递送系统、其制备方法和用途
PCT/CN2019/072556 WO2019141274A1 (zh) 2018-01-22 2019-01-21 用于靶向活化cd44分子的金属框架化合物纳米载体递送系统、其制备方法和用途
PCT/CN2019/072477 WO2019141267A1 (zh) 2018-01-22 2019-01-21 用于靶向活化cd44分子的重组仿生纳米载体递送系统、其制备方法和用途
PCT/CN2019/072560 WO2019141276A1 (zh) 2018-01-22 2019-01-21 用于靶向活化cd44分子的介孔/中空二氧化硅纳米载体递送系统、其制备方法和用途
PCT/CN2019/072499 WO2019141271A1 (zh) 2018-01-22 2019-01-21 用于靶向活化cd44分子的脂质体纳米载体递送系统、其制备方法和用途
PCT/CN2019/072573 WO2019141278A1 (zh) 2018-01-22 2019-01-21 用于靶向活化cd44分子的纳米钙载体递送系统、其制备方法和用途
PCT/CN2019/072473 WO2019141266A1 (zh) 2018-01-22 2019-01-21 用于靶向活化cd44分子的水凝胶纳米载体递送系统、其制备方法和用途
PCT/CN2019/072465 WO2019141264A1 (zh) 2018-01-22 2019-01-21 用于靶向活化cd44分子的树枝状聚合物纳米载体递送系统、其制备方法和用途
PCT/CN2019/072471 WO2019141265A1 (zh) 2018-01-22 2019-01-21 用于靶向活化cd44分子的胶束纳米载体递送系统、其制备方法和用途

Family Applications Before (4)

Application Number Title Priority Date Filing Date
PCT/CN2019/072559 WO2019141275A1 (zh) 2018-01-22 2019-01-21 用于靶向活化cd44分子的硅质体纳米载体递送系统、其制备方法和用途
PCT/CN2019/072556 WO2019141274A1 (zh) 2018-01-22 2019-01-21 用于靶向活化cd44分子的金属框架化合物纳米载体递送系统、其制备方法和用途
PCT/CN2019/072477 WO2019141267A1 (zh) 2018-01-22 2019-01-21 用于靶向活化cd44分子的重组仿生纳米载体递送系统、其制备方法和用途
PCT/CN2019/072560 WO2019141276A1 (zh) 2018-01-22 2019-01-21 用于靶向活化cd44分子的介孔/中空二氧化硅纳米载体递送系统、其制备方法和用途

Family Applications After (4)

Application Number Title Priority Date Filing Date
PCT/CN2019/072573 WO2019141278A1 (zh) 2018-01-22 2019-01-21 用于靶向活化cd44分子的纳米钙载体递送系统、其制备方法和用途
PCT/CN2019/072473 WO2019141266A1 (zh) 2018-01-22 2019-01-21 用于靶向活化cd44分子的水凝胶纳米载体递送系统、其制备方法和用途
PCT/CN2019/072465 WO2019141264A1 (zh) 2018-01-22 2019-01-21 用于靶向活化cd44分子的树枝状聚合物纳米载体递送系统、其制备方法和用途
PCT/CN2019/072471 WO2019141265A1 (zh) 2018-01-22 2019-01-21 用于靶向活化cd44分子的胶束纳米载体递送系统、其制备方法和用途

Country Status (8)

Country Link
US (2) US20200397926A1 (zh)
EP (1) EP3744317A4 (zh)
JP (2) JP7436367B2 (zh)
KR (1) KR20200111185A (zh)
CN (9) CN110545799B (zh)
AU (1) AU2019208796B2 (zh)
CA (1) CA3087606A1 (zh)
WO (9) WO2019141275A1 (zh)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113577300A (zh) * 2021-06-29 2021-11-02 首都医科大学附属北京儿童医院 一种靶向脂质体药物递送系统及其制备方法和应用
WO2023030524A1 (zh) * 2021-09-06 2023-03-09 北京茵诺医药科技有限公司 靶向动脉粥样硬化脂质体纳米载体递送系统及其制备方法

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3610859A4 (en) * 2017-04-12 2021-01-27 Beijing Inno Medicine Co., Ltd. CERASOM DELIVERY SYSTEM FOR USE IN THE TARGETED ACTIVATION OF CD44 MOLECULES, MANUFACTURING METHOD FOR IT AND USE
CN111569053A (zh) * 2020-03-13 2020-08-25 中国科学院长春应用化学研究所 一种通过调控肿瘤代谢行为增强免疫治疗的纳米酶及其制备方法与应用
CN111494320A (zh) * 2020-04-24 2020-08-07 上海交通大学医学院附属仁济医院 一种载糖皮质激素的纳米载体及其制备和应用
CN111514289A (zh) * 2020-04-28 2020-08-11 天津大学 新冠病毒免疫纳米颗粒制剂的合成方法
CN111603576B (zh) * 2020-05-29 2023-06-02 成都纽瑞特医疗科技股份有限公司 一种锝[99mTc]炭微球注射液及其制备方法和用途
CN111701032A (zh) * 2020-06-23 2020-09-25 重庆大学附属肿瘤医院 兼具药物控释及成像功能的介孔氧化硅复合体的制备方法
CN112076158B (zh) * 2020-08-28 2023-12-08 西南民族大学 一种治疗慢性肾炎的脂质体-纳米粒复合体
CN111821470B (zh) * 2020-09-01 2022-08-12 中南大学 包载甲氨蝶呤的铁-鞣酸配合物及其制备方法与应用
CN112426533A (zh) * 2020-12-01 2021-03-02 南通大学附属医院 一种纳米碳酸钙载药系统、其制备方法及其应用
CN114276563B (zh) * 2020-12-14 2023-02-24 南京工业大学 医用水凝胶的制备方法、水凝胶及敷料
CN114788871B (zh) * 2021-01-25 2024-02-06 山东大学 寡聚芦丁在制备肿瘤靶向产品中的应用及寡聚芦丁-硼替佐米肿瘤靶向递药系统
CN113244172B (zh) * 2021-03-29 2023-05-23 中山大学附属第一医院 一种siRNA和抗癌药靶向共递送系统及其制备方法和应用
CN113402684B (zh) * 2021-07-02 2022-02-18 肇庆医学高等专科学校 一种磁性表面印迹材料的制备方法及其在识别与拆分氨氯地平中的应用
CN113480855B (zh) * 2021-07-26 2022-10-18 怡力精密制造有限公司 硅橡胶及硅橡胶的制备方法
CN113995887B (zh) * 2021-10-14 2022-06-28 四川大学华西医院 一种软骨修复纳米凝胶复合体系的制备方法及应用
CN113855635A (zh) * 2021-10-20 2021-12-31 陇南市第一人民医院 一种阿加曲班注射液脂质体及其制备方法
CN113995854B (zh) * 2021-11-09 2023-04-14 中山大学 一种谷胱甘肽敏感的纳米载药系统及其制备方法和应用
CN115317624B (zh) * 2021-12-01 2024-07-26 武汉纺织大学 一种主动靶向骨肿瘤的液态金属-金属有机框架纳米载药材料及其制备方法和应用
CN114129536A (zh) * 2021-12-03 2022-03-04 深圳市融创金石科技有限公司 仿生普鲁士蓝复合材料及其制备方法和应用
CN114209854A (zh) * 2021-12-31 2022-03-22 山东大学齐鲁医院(青岛) 一种磁流体复合显影剂及其在骨内血管显像领域的应用
CN114674966B (zh) * 2022-03-28 2024-09-13 武汉海关技术中心 一种β-受体阻断剂和β2-受体激动剂萃取材料的制备方法
CN115006547B (zh) * 2022-05-06 2024-01-26 南京大学 负载氯沙坦钾的响应性zif-8纳米颗粒及其制备方法和应用
CN115040659A (zh) * 2022-05-30 2022-09-13 浙江大学 一种无毒聚阳离子高分子载体材料
CN115364239B (zh) * 2022-06-02 2024-01-30 徐州医科大学 一种具有靶向易损动脉粥样硬化斑块实现成像的纳米粒子及其制备方法和应用
CN115475255A (zh) * 2022-06-14 2022-12-16 澳门科技大学 一种酶响应型二氧化硅释纳米制剂、制备方法及应用
CN115887690A (zh) * 2022-08-26 2023-04-04 上海交通大学医学院附属第九人民医院 用于治疗炎症的载药纳米体系、其制备方法及其应用
CN115400226A (zh) * 2022-08-29 2022-11-29 威高集团有限公司 一种同时具有抗菌抗炎功能的ZIF-8@Rutin纳米复合材料及其制备方法以及应用
CN115998910B (zh) * 2023-01-06 2023-11-17 山西医科大学 一种靶向ha的核素小分子蛋白探针及其应用
WO2024178502A1 (en) * 2023-02-27 2024-09-06 Valorisation Hsj, Limited Partnership Layer-by-layer modified lipid nanoparticles, uses thereof and methods for producing the same
CN116942850B (zh) * 2023-09-21 2023-12-05 北京茵诺医药科技有限公司 一种用于易损斑块的纳米药物递送系统

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001039815A2 (en) * 1999-12-03 2001-06-07 The Regents Of The University Of California Targeted drug delivery with a cd44 receptor ligand
CN105412947A (zh) * 2015-12-18 2016-03-23 复旦大学附属中山医院 一种ct/mr双模态纳米探针及其制备方法
CN105749296A (zh) * 2016-02-26 2016-07-13 西南大学 一种溃疡性结肠炎组织靶向分子及其应用
CN107485603A (zh) * 2017-08-02 2017-12-19 中国药科大学 一种自组装的透明质酸－难溶性前药包覆的包载活性药物的脂质体纳米给药系统及其制备方法

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH09110722A (ja) * 1995-10-20 1997-04-28 Toray Ind Inc 抗腫瘍活性物質の腫瘍細胞内導入用イムノリポソーム及びその調製法
CN101438252A (zh) * 2004-10-07 2009-05-20 爱莫里大学 多功能纳米粒子共轭体及其应用
WO2008005509A2 (en) * 2006-07-06 2008-01-10 Massachusetts Institute Of Technology Methods and compositions for altering biological surfaces
WO2008079898A1 (en) * 2006-12-20 2008-07-03 Pharmwest, Inc. Methods and topical formulations comprising colloidal metal for treating or preventing skin conditions
FR2921660B1 (fr) * 2007-10-01 2015-09-25 Centre Nat Rech Scient Nanoparticules hybrides organiques inorganiques a base de carboxylates de fer.
WO2010120905A2 (en) * 2009-04-15 2010-10-21 Board Of Trustees Of Michigan State University Novel nano-probes for molecular imaging and targeted therapy of diseases
US20120082616A1 (en) * 2010-09-24 2012-04-05 Mallinckrodt Llc Aptamer Conjugates for Targeting of Therapeutic and/or Diagnostic Nanocarriers
CN103191411A (zh) * 2013-04-28 2013-07-10 中国药科大学 环孢素a和两亲性透明质酸衍生物的组合物及其制备方法
CN104491886A (zh) * 2014-12-30 2015-04-08 东华大学 一种具有还原/酶双响应和靶向性的介孔硅纳米粒子的制备方法
CN104815340A (zh) * 2015-04-07 2015-08-05 天津医科大学 磁共振成像导向的靶向金属有机骨架药物载体的制备方法
CN105078895B (zh) * 2015-08-14 2018-02-09 中国人民解放军第二军医大学 一种脑靶向的仿生纳米药物递释系统的制备及在治疗脑胶质瘤中的应用
CN105343895B (zh) * 2015-12-04 2019-10-15 福州大学 一种双重靶向的载熊果酸/siRNA的荧光介孔二氧化硅-透明质酸及应用
CN105664250A (zh) * 2016-01-27 2016-06-15 苏州佰通生物科技有限公司 一种可注射可降解温敏性水凝胶及其制备方法
CN105708800B (zh) * 2016-02-02 2017-09-12 湖南师范大学 一种靶向乳腺癌干细胞的洛伐他汀硅质体
SG11201810628XA (en) * 2016-06-03 2018-12-28 M et P Pharma AG Nasal pharmaceutical compositions with a porous excipient
CN106362172B (zh) * 2016-08-26 2019-04-30 郑州大学 透明质酸修饰的介孔碳酸钙药物组合物的制备方法及应用
CN106512023B (zh) * 2016-12-02 2019-08-27 武汉理工大学 双功能介孔硅球复合靶向给药系统的制备方法
CN106798726B (zh) * 2016-12-20 2019-08-23 上海纳米技术及应用国家工程研究中心有限公司 一种靶向性载药硅质体及制备和应用
CN106729737A (zh) * 2016-12-30 2017-05-31 中国药科大学 一种“脱壳”式智能纳米药物复合物及其制备方法
CN107213476B (zh) * 2017-07-12 2021-01-19 重庆医科大学 一种透明质酸修饰的硅包裹载药磷脂液态氟碳纳米球超声造影剂及其制备方法

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001039815A2 (en) * 1999-12-03 2001-06-07 The Regents Of The University Of California Targeted drug delivery with a cd44 receptor ligand
CN105412947A (zh) * 2015-12-18 2016-03-23 复旦大学附属中山医院 一种ct/mr双模态纳米探针及其制备方法
CN105749296A (zh) * 2016-02-26 2016-07-13 西南大学 一种溃疡性结肠炎组织靶向分子及其应用
CN107485603A (zh) * 2017-08-02 2017-12-19 中国药科大学 一种自组装的透明质酸－难溶性前药包覆的包载活性药物的脂质体纳米给药系统及其制备方法

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CURR ATHEROSCLER REP., vol. 3, no. 2, 2001, pages 125 - 35
MULLERCOLLEAGUES: "Circadian Variation and Triggers of Onset of Acute Cardiovascular Disease", CIRCULATION, vol. 79, no. 4, 1989, pages 733 - 43
See also references of EP3744317A4

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113577300A (zh) * 2021-06-29 2021-11-02 首都医科大学附属北京儿童医院 一种靶向脂质体药物递送系统及其制备方法和应用
WO2023030524A1 (zh) * 2021-09-06 2023-03-09 北京茵诺医药科技有限公司 靶向动脉粥样硬化脂质体纳米载体递送系统及其制备方法

Also Published As

Publication number Publication date
CN110545793A (zh) 2019-12-06
AU2019208796A1 (en) 2020-07-30
CN110545795A (zh) 2019-12-06
CN110573145B (zh) 2021-02-26
CN110573144B (zh) 2021-02-26
CN110545799B (zh) 2021-02-26
CN110536680A (zh) 2019-12-03
US20200397926A1 (en) 2020-12-24
CN110545793B (zh) 2021-02-26
WO2019141264A1 (zh) 2019-07-25
JP7436367B2 (ja) 2024-02-21
CA3087606A1 (en) 2019-07-25
CN110545798A (zh) 2019-12-06
CN110573145A (zh) 2019-12-13
WO2019141274A1 (zh) 2019-07-25
JP2021510703A (ja) 2021-04-30
CN110545798B (zh) 2021-02-26
WO2019141265A1 (zh) 2019-07-25
JP2024014986A (ja) 2024-02-01
CN110573144A (zh) 2019-12-13
CN110545794A (zh) 2019-12-06
CN110545800B (zh) 2021-02-26
WO2019141278A1 (zh) 2019-07-25
EP3744317A4 (en) 2021-12-22
WO2019141275A1 (zh) 2019-07-25
KR20200111185A (ko) 2020-09-28
AU2019208796B2 (en) 2024-07-04
CN110545800A (zh) 2019-12-06
CN110545795B (zh) 2021-02-26
WO2019141267A1 (zh) 2019-07-25
CN110545794B (zh) 2021-02-26
WO2019141276A1 (zh) 2019-07-25
EP3744317A1 (en) 2020-12-02
WO2019141266A1 (zh) 2019-07-25
US20240148913A1 (en) 2024-05-09
CN110536680B (zh) 2021-02-26
CN110545799A (zh) 2019-12-06

Similar Documents

Publication Publication Date Title
WO2019141271A1 (zh) 用于靶向活化cd44分子的脂质体纳米载体递送系统、其制备方法和用途
CN110402137B (zh) 一种用于靶向活化cd44分子的硅质体递送系统、其制备方法和用途
CN112206326B (zh) 用于靶向活化cd44分子的氨基酸自组装纳米载体递送系统、其制备方法和应用
CN112274651A (zh) 用于靶向活化cd44分子的聚多巴胺纳米载体递送系统、其制备方法和应用
AU2024223989A1 (en) Liposomal nanocarrier delivery system for targeting active CD44 molecule, preparation method therefor, and uses thereof

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 19741349

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 3087606

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2020538853

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2019208796

Country of ref document: AU

Date of ref document: 20190121

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2019741349

Country of ref document: EP

Effective date: 20200824